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The choroid plexus (CP) and blood-brain barrier (BBB) control the movement of several drugs
and endogenous compounds between the brain and systemic circulation. The multidrug resistance
associated protein (Mrp) efflux transporters form part of these barriers. Several Mrp transporters
are positively regulated by the transcription factor nuclear factor erythroid-2-related factor (Nrf2)
in liver. The Mrps, Nrf2 and Nrf2-dependent genes are cytoprotective and our aim was to examine
basal gender differences in expression of Mrp transporters, Nrf2 and Nrf2-dependent genes (Nqo1
and Ho-1) in the brain-barriers. Previous studies have shown higher expression of Mrp1, Mrp2
and Mrp4 in female mouse liver and kidney. We hypothesized that similar renal/hepatic genderspecific patterns are present in the brain-barrier epithelia interfaces. qPCR and immunoblot
analyses showed that Mrp4, Ho-1 and Nqo1 expression was higher in female CP. Mrp1, Mrp2
and Nrf2 expression in the CP had no gender pattern. Female Mrp1, Mrp2 and Mrp4 mouse brain
expressions in remaining brain areas, excluding CP, were higher than male. Functional analysis
of Mrp4 in CP revealed active accumulation of the Mrp4 model substrate fluo-cAMP. WT female
CP had 10-fold higher accumulation in the vascular spaces than males and 60% higher than Mrp4/-

females. Probenecid blocked all transport. Methotrexate did as well except in Mrp4-/- females

where it had no effect, suggesting compensatory induction of transport occurred in Mrp4-/-.
Collectively, our findings indicate significant gender differences in expression of Mrp transporters
and cytoprotective genes in the CP and BBB.

Katiria Marie Flores, University of Connecticut, 2017

In addition to identifying the basal gender differences of these transporters, another goal of the
present study was to examine the gender differences of these genes in lateral CP and brain (with
the lateral CP removed) in the response to an hepatotoxic dose of acetaminophen (APAP) in wildtype (WT) and Nrf2-/- mice. We also ascertained the gender-dependent response to APAP of
Cyp2e1, an enzyme responsible for the bioactivation of APAP to reactive intermediates and
expressed equivalently in WT males and females. Our results indicate that hepatotoxic doses of
APAP increase Abc drug transporters gene expression in male, but not female mouse CP and brain.
There are no gender-dependent differences or induction after APAP in Cyp2e1 expression in CP
or brain. Together, the data suggest that gender dependent expression of stress response genes
(Nqo1 and Ho-1) and Mrps at blood-brain interfaces may influence the potential neurotoxicity of
APAP differentially in males and females.
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CHAPTER 1
CHAPTER 1. INTRODUCTION
1.1 Brain Barriers significance & background
Neurons are exquisitely and adversely sensitive to toxicants and pathogens. Normally the
impermeable blood-cerebrospinal fluid (CSF) barrier (BCSFB) and the blood-brain barrier (BBB)
act together to protect the central nervous system (CNS) from potentially injurious agents in blood.
Historically, the BBB has received more pharmacologic, toxicologic, and pathologic attention than
the BCSFB, or choroid plexus (CP). However, both of these barriers are of unique interest to the
physiologist and toxicologist because they control the movement of various compounds between
the brain and systemic circulation. Access to the CNS by endogenous (e.g. peptides, metabolites,
signaling molecules) as well as exogenous compounds (e.g. toxicants, drugs, nutrients) is precisely
controlled by the BBB and the BCSFB. Bidirectional and selective movement of compounds
across the BBB and BCSFB often poses a challenge to CNS targeted pharmacotherapy. Although
both barriers restrict what gets inside and kept out of the brain, there are fundamental structural
and functional differences between the two. Conceptualization of the BBB and BCSFB as one
barrier is common, albeit erroneous, and reflects a need for more research to delineate the different
functional characteristics of the unique membrane boundaries that separate blood, CSF, and brain.

1.1.2 CP Function and Structure
The CPs are localized in the ventricular system of the brain and form one of the interfaces
between the blood and the CNS. There are four CP, two in each lateral ventricle, one in the third
ventricle and one in the fourth ventricle with a complex, rather different structure (Figure 1.1).
The CP as a whole is composed of the epithelial layer adjacent to the ventricle, a basal lamina, to
1

which the epithelial cells are anchored, and an inner core surrounded by a rich capillary bed (Figure
1.2). This arrangement allows the transfer of compounds from one compartment to another. The
CP is continuous with and derives from the ependyma, but differs fundamentally from it by the
presence of tight junctions at the apical membrane, which provide the anatomic basis of the bloodCSF barrier. The epithelial layer folds around each of the numerous capillaries, forming fronds of
various shapes that project into the CSF thus increasing the ventricular surface area of the CP. The
epithelial cells of the CP are cuboidal and multiciliated; the cilia are thought to aid the flow of
fluid through the ventricular system, therefore helping with the CSF circulation. The blood flow
to the CP is 3 ml·g-1 ·min-1 , which is 10 times higher than the blood flow to the brain parenchyma
and five times higher than that to the kidney (Chodobski et al., 1994; Damkier et al., 2010). CSF
production is a key feature of the CP and serves to buoy the brain, adjust the intracranial blood
volume, and acts as a vehicle for delivering nutrients to the brain and removing waste.
Understanding the control of CSF formation has been a challenge, but is clinically important due
to its relation to brain fluid disorders such as congenital hydrocephaly, one of the most common
birth defects, and neurodegenerative diseases such as Alzheimer’s, the incidence of which
increases dramatically with age. Pharmacological attempts to regulate CSF formation have
focused on altering ion movement via transporters in the membranes of CP epithelium (Johanson
et al., 2008). Other important features of the CP include the supply of various micronutrients (such
as vitamin C, folates, vitamin B12, etc.) via specific transport mechanisms, the synthesis and
secretion of numerous peptides and proteins into the CSF, and the clearance of metabolites and
other harmful compounds from CSF to the blood. CP cells are also rich in mitochondria that supply
energy needed for active transport. Due to tightly sealed CP epithelial tight junctions, free
exchange of compounds is limited. Overall, the CP is similar to the kidney, and one important
2

function appears to be the removal of potentially toxic xenobiotics and metabolic wastes from CSF
to blood for eventual body excretion. Although organic anion (OA) transport mechanisms in the
kidney and liver have been well-characterized, experimental assessment of the mechanisms used
in other tissues, such as the CP, is limited by the small size and anatomic inaccessibility of the
transporting epithelia (Villalobos et al., 1997; Villalobos et al., 2002). The CP is a polarized tissue;
transporters typically route to the brush border membrane (BBM) and basolateral membranes
(BLM) facing towards the CSF and plasma, respectively. In addition, transepithelial transport has
been found to be selective. Abc transporters, such as multidrug resistance proteins (Mrps), are
current candidates to account for transport of OAs in CP as is proposed in the kidney (Figure 1.3).

1.1.2 Blood brain barrier
The BBB is composed of a monolayer of brain capillary endothelial cells that are fused
together by tight junctions. Under normal physiological conditions, these tight junctions form a
continuous, almost impermeable, cellular barrier that prevents the passive influx of a variety of
substances with the exception of the smallest, lipid soluble molecules (Reese and Karnovsky,
1967). The absence of fenestrations, vesicular traffic, and pinocytosis in brain capillary endothelia
further restrict free flow between brain interstitial fluid and blood. The endothelial cells of the
BBB contain numerous membrane transporters involved in the influx/efflux of various essential
substrates such as electrolytes, nucleosides, amino acids, and glucose (Figure 1.4). The BBB
membrane transporters prevents entry into the brain of most drugs from the blood. Therefore, the
presence of this barrier makes difficult the development of new treatments of brain diseases.

1.2 Role of Multidrug Resistance Proteins (Mrps)
3

Transport of drugs and metabolites is facilitated by multi-specific transporters organic
anion transporters (Oats), organic anion transport peptide (Oatp) and Abc transporters. Abc
transporters are responsible for translocating an enormous variety of substrates across cellular
membranes. They play important roles in clearing the brain of unwanted substances and protecting it
from potentially harmful material in the circulation. Modification of transport activity can alter the
CSF content of natural as well xenobiotic compounds. The Abcc subfamily of Abc transporters

consists of 13 members in mammals. The largest group of Abcc transporters is Mrps, which
contain 10 members, including MRP1/Abcc1, MRP2/Abcc2, MRP3/Abcc3, MRP4/Abcc4,
MRP5/Abcc5,

MRP6/Abcc6,

MRP7/Abcc10,

MRP8/Abcc11,

MRP9/Abcc12,

and

MRP10/Abcc13. Although the functions of the family members may turn out to be diverse, the
Mrps play a key role in cellular protection by removing xenobiotics and endogenous substrates
that can accumulate in tissue and lead to toxicity.

The Abcc transporters are expressed

differentially in the liver, kidney, intestine, brain, and other tissues. In CP, Mrp1 and 4 are
localized in the basolateral membrane (Gao et al., 1999; Leggas et al., 2004) while Mrp2 is located
in the apical membrane. Mrp3, -5 and -6 have not been analyzed histologically in CP due to lack
of antibody tissue specificity. Abcc transporters are capable of pumping a wide variety of
substrates out of the cell including chemotherapeutic drugs and antiretroviral agents, anti-cancer
agents, as well as several endogenous ligands, including conjugated bile acids, glucuronidated
estrogens, and leukotrienes. Hooijberg et al. 1999 (Hooijberg et al., 1999), have shown that Mrp1
can cause resistance to short-term methotrexate (MTX) exposure. The same was found for Mrp4
(Chen et al., 2002). In spite of recently increased interest in OA transporters, their characterization
in the brain is still limited. Despite their differences in substrate specificity and affinities, the ability
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to transport a wide range of anticancer drugs and their presence in tumors make them prime
suspects in unexplained cases of drug resistance.

1.2.1 Mrp4 and its role in OA transport.
Abcc4, also known as Mrp4, belongs to a large family of transmembrane proteins involved
in active transport of substrates out of cells. This transporter can be found in a variety of human
tissues, with high levels of expression in the kidney and prostate, while lower levels are found in
the liver, testes, ovary, lung, adrenal gland, and in various neurons and blood cells. The structure
of Mrp4 in humans has been characterized by a P-glycoprotein like core with two transmembrane
domains and two nucleotide-binding domains (Maher et al., 2005). Human and mouse Mrp4 also
functions in the transport of cyclic nucleotides, such as cAMP, which in humans has been shown
to be implicated in the development of cancers such as pancreatic adenocarcinoma and acute
myeloid leukemia. Mrp4 has also been shown to transport several additional compounds of
pharmacological and physiological importance in humans including endogenous substrates such
as eicosanoids, urate, and conjugated steroids involved in cell signaling, as well as a variety of
antiviral, cytostatic, antibiotics, and cardiovascular drugs and their metabolites. The variety of
substrates also includes anticancer drugs such as methotrexate that has been implicated in the
treatment of cancer in lungs and ovaries. Interestingly, Maher and colleagues showed that Mrp4
expression is tissue specific, significantly higher in kidneys compared to liver, and gender
dependent, being expressed at a rate 2 and 2.5 times higher in females than in males in both liver
and kidney, respectively (Maher et al., 2005). This efflux transporter is unique among Abcc
transporters due to its dual localization in polarized cells. In the liver and CP Mrp4 is expressed
at the basolateral membrane, while in brain capillary endothelium and renal proximal tubule cells
5

Mrp4 is expressed at the apical membrane (Russel et al., 2008). The broad substrate specificity
of Mrp4 confers to this transporter multiple physiological roles, including the protection of the
brain from different drugs or alteration of signaling pathways. Since Mrp4 transports nucleoside
analogues and antiviral drugs, mRNA and protein expression may have an effect on anticancer
and HIV therapy.

1.3 Other brain detoxification systems at the brain interfaces
In addition to the physical barriers provided by the tight junctions along the BBB and
blood-CSF barrier, the presence of drug-metabolizing enzymes at the two interfaces provides an
additional enzymatic barrier. Drug-metabolizing enzymes have been identified in the cerebral
microvessels, CPs, leptomeninges, and in some circumventricular organs (Ghersi-Egea et al.,
1995). These include the cytochrome P450 hemoproteins, several cytochrome P450-dependent
monooxygenases, NADPH-cytochrome P450 reductases, glutathione (GSH) peroxidases, and
epoxide hydrolases (Ghersi-Egea et al., 1995). Degradation or biotransformation products are
likely eliminated from the brain either by specific transport systems within the BBB or by diffusion
from the parenchyma into the CSF by bulk flow (Ghersi-Egea et al., 1995). The presence of drugmetabolizing enzymes within the two brain compartments suggests an important role in the
detoxification of potentially harmful xenobiotics and pharmacological agents.

1.3.1 Phase I drug-metabolizing enzymes
Phase I biotransformation reactions introduce or expose functional groups on drugs with
the goal of increasing the polarity of the compound. The primary site of metabolism occurs in
liver. Additional metabolism occurs in gastrointestinal epithelial, renal, skin, lung tissues and
6

brain tissue. In general, the distribution of drug-metabolizing CYPs in the brain is heterogeneous,
with expression levels varying among different brain regions. They play a critical role in the
metabolism of many drugs and xenobiotics with each cytochrome isozyme responding differently
to exogenous chemicals in terms of its induction and inhibition. Phase I reactions are broadly
grouped into three categories, oxidation, reduction, and hydrolysis. As most small molecule drugs
are lipophilic in nature, drug metabolism converts these hydrophobic compounds into more water
soluble compounds that can be excreted. Typically, oxidation is the most common phase I
reaction. The hepatic cytochrome P450 system is the most important of the phase I oxidation
systems. The cytochrome P450s are members of a superfamily of monoxygenases that catalyze
the oxidative metabolism of xenobiotics, the initial step in the biotransformation and elimination
of a wide variety of drugs and other compounds. Studies have shown that Cyps are actively present
in the rat brain.

Some isozymes, such as CYP1A1, CYP2B, CYP2E1 and CYP3A, are

predominantly found in neurons, whereas others are found in both neurons and glial cells. Many
known hepatic CYP inducers have similar effects in the brain, two examples are ethanol and
acetone induction of CYP2E1 (Sanchez-Catalan et al., 2008). Most brain CYPs metabolize
substrates with similar affinities, and relative substrate and inhibitor selectivity, to their hepatic
counterparts. However, the subcellular localization of brain CYPs is often different from hepatic
CYPs, partly owing to the differences in cellular structure between hepatocytes and different areas
of the brain. Furthermore, CYP protein expression was mapped across brain regions and cell types,
and the analysis showed that their expression levels vary greatly among specific brain regions and
that, at the cellular level, expression can be as high as levels in hepatocytes (Meyer et al., 2007).
Although the responses to drugs acting on the CNS are not always directly related to drug and
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metabolite levels circulating in the plasma, brain CYPs are concentrated near drug targets in
specific regions and cell types, and can potentially have a considerable impact on local metabolism.

There are sex-based differences in the expression of some hepatic CYPs. In some cases
they have been related to drug-specific susceptibility. As in the liver, the Cyp enzymes play an
important role in the development of acetaminophen (APAP) induced renal toxicity.

Cyp

inhibitors have been to reduce renal damage; while Cyp activators increase APAP induced renal
damage (Mazer and Perrone, 2008). Cyp2E1 is most highly involved in the bioactivation of APAP
in the kidney and is also inducible by testosterone. Studies in which female mice were treated
with testosterone and male mice underwent castration resulted in increased and reduced APAP
induced nephrotoxicity, respectively (Hart et al., 1994; Hoivik et al., 1995). This demonstrates
that testosterone accounts for the greater susceptibility of male mice to APAP induced renal
toxicity (Mazer and Perrone, 2008). Only a few studies have investigated gender differences in
the expression of CYPs in the brain, several of which assessed CYP19, which metabolically
converts androgens to estrogens (Simpson et al., 1994). Male rats exhibit higher CYP19 activity
in certain brain regions, such as the hypothalamus, compared to females (Roselli and Resko, 1997);
however, sex differences in the expression of CYP19 were not observed in the adult human brain
(Watzka et al., 1999).

1.3.2 Phase II drug-metabolizing enzymes
Phase II biotransformation reactions generally serve as a detoxifying step in drug
metabolism. Phase II drug metabolizing enzymes play an important role in biotransformation of
endogenous compounds and xenobiotics to forms that can be excreted more easily, as well as in
8

the metabolic inactivation of pharmacologically active compounds.

The reactions of these

enzymes are commonly described as conjugation reactions and include glucuronidation,
sulfonation, glycine/glutamine conjugation, acetylation, methylation, and glutathione (GSH)
conjugation (Bock et al., 1987; Jancova et al., 2010). Conjugations allow linking a new group
either to the parent drug or to phase I metabolites. For example, they are known to play a role in
APAP detoxification. There is evidence of APAP-GSH conjugations after APAP overdose. GSH
conjugation reaction protects against reactive metabolites. The mechanism of action might be
tissue

specific,

a

study

in

which

L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydroxy-

5isoxaoleacetic acid (AT-125), which inhibits metabolism of APAP-GSH conjugates, and
probenecid, which inhibits transport of APAP-GSH metabolites, were administered,
nephrotoxicity was reduced without changes in protein arylation (Hart et al, 1996). These results
are not reproduced in the liver, suggesting unique, independent processes at work. These enzymes
play an important role in the protection against reactive molecules such as electrophilic xenobiotics
(anticancer drugs, pollutants or carcinogens) or endogenous quinones, epoxides, and
hydroperoxides formed as secondary metabolites during periods of oxidative stress.

1.4 Role of transporters in drug resistance
Disorders of the central nervous system (CNS) remain difficult to treat pharmacologically
due to poor drug permeation of brain barriers such as the blood-brain and blood-cerebrospinal fluid
(CSF) barriers. Drug passage across these biological membranes is possible through multiple
mechanisms.

One mechanism depends on carrier-mediated transporters, among which, we

distinguish those requiring ATP-dependent hydrolysis as the first step in catalysis (e.g. Abc
transporters such as multidrug resistance-associated protein (Mrp), and breast cancer resistance
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protein (Bcrp)). Drug efflux transporters including the P-glycoprotein pump (Pgp), the multidrugresistant protein-1(Mrp1) and the Bcrp actively pump drugs such as chemotherapeutics out of the
cells, thereby reducing their intracellular accumulation and making the cell insensitive to the drugs.
Therefore, the expression and activity of these transporters play a critical role in drug resistance.
Overexpression of these drug transporters in tumors has been demonstrated by several studies. For
example, the Mrp4 gene is overexpressed in cisplatin resistant human cancer cell lines with
decreased drug accumulation (Taniguchi et al., 1996). Studies have shown that Mrp1 is highly
expressed in neuroblastoma, a cancer of embryonal neural crest cells, which is the most common
solid tumor of early childhood. A large number of chemotherapeutic drugs used in the treatment
of neuroblastoma are substrates of Mrp1, leading to the conclusion that Mrp1 may influence the
clinical outcome by mediating resistance to cytotoxic drugs used during treatment (Deeley and
Cole, 2006). In general, overexpression of these pumps in tumor cells gives them the ability to
evade the effects of drugs such as cisplatin, fluoropyrimidines, doxorubicin and etoposide in
different types of cancer (Jedlitschky et al., 1996; Zelcer et al., 2001). Therefore, the use of
chemomodulators to inhibit efflux transport has been tested in an attempt to overcome this
resistance (Baumert and Hilgeroth, 2009; Zhou et al., 2008). Interestingly, there is a large overlap
in the substrate specificities of these Abc transporters; therefore, the absence or decreased activity
of one of these transporters is often compensated by one or more other members (Table A.3). This
presents a major challenge for the use of many (anticancer) drugs, as most currently used
anticancer drugs are substrates of these transporters. Consequently, it has at times been difficult
to understand the contribution of each transporter to drug disposition (Klaassen and Aleksunes,
2010; Vlaming et al., 2006). Since GSH-, glucuronide-, sulfate-conjugates and organic anions
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such as methotrexate, indinavir, cisplatin, vincristine and etoposide are all Mrp substrates, Mrps
are also crucial in human drug disposition and toxicity.

1.5 Modulators of Abc transporters: hormonal control, stress, compensation phenomenon.
Abc-type multidrug transporters mediate drug resistance by energy-dependent drug efflux
from cells and by influencing the pharmacokinetics of substrate drugs through directional transport
across the epithelial membranes in the body (Reichel et al., 2010). The expression of several Mrp
efflux transporters is regulated by Nuclear factor (erythroid-derived 2)-like-2 factor (Nrf2), a
transcription factor, via Nrf2-mediated responses to oxidative stress (Aleksunes et al., 2008). The
treatment of mice with the Nrf2 activator chemicals oltipraz, ethoxyquin and butylated
hydroxyanisole induces hepatic levels of Mrp2–4 mRNA (Merrell et al., 2008). Administration of
toxic acetaminophen (APAP) doses to C57BL/6J mice generates electrophilic stress and
subsequently increases levels of hepatic Nqo1, Gclc and Mrp1–4. Aleksunes et al. (Aleksunes et
al., 2008), showed that APAP treatment increased hepatic Mrp3 and Mrp4 mRNA and protein in
WT, but not Nrf2-null mice. Furthermore, they showed Mrp1 was induced in both genotypes after
APAP, suggesting that elevated expression of this transporter was independent of Nrf2. These
results suggest that Nrf2 mediates induction of Mrp3 and Mrp4 after APAP but does not affect
Mrp1.
Many phase II enzymes and transporters (phase III) are expressed in a sexually dimorphic
manner in which there is typically higher expression in female mice. Sex steroids often mediate
gender-dependent gene expression in kidney and liver, and we may observe the same phenomenon
in CP. Recent studies conducted to analyze the effects of the sex hormone background in rat CP
transcriptome have shown that genes involved in drug metabolism, metabolism of xenobiotics by
cytochrome P450, and pentose and glucuronate interconversions, were significantly down11

regulated only in females in response to gonadectomy (Quintela et al., 2013).

It is well

documented that expresion of some phase III transporters display sex differences. For example,
Mrp3 and Mrp4 are more highly expressed in female kidney compared to male, and it is also
known that there is higher hepatic Mrp1 and Mrp4 expression in female mice (Cheng et al., 2008).
Furthermore, renal Mrp4 mRNA and protein expression are repressed by androgens [5alphadihydroxytestosterone (DHT)], but increase in castrated mice (Maher et al., 2006). Such hormonal
alterations of Mrp transporters may manifest as differences in renal clearance of Mrp substrates
and therefore variations in drug treatment between gender.
Basolateral expression of Mrps of CP may be responsible for clearance of drugs, their
metabolites and toxic compounds from the CSF to the blood. Due to the wide variety of substrates,
we may observe compensatory mechanisms by other detoxification enzymes when expression of
one Mrp transporter is reduced. For example, rats deficient in Mrp2 compensate by inducing
hepatic Mrp3 and renal Mrp4, which helps to divert the elimination of bilirubin from the liver to
the kidney (Kuroda et al., 2004). Furthermore, Bain and Feldman (Bain and Feldman, 2003),
showed that FVB mice lacking Mrp1 (FVB/Mrp1-/- mice) had alteration in hepatic phase III
transporter mRNA expression. They showed an induction of Mrp2 and Mrp5 between FVB mice
and FVB/Mrp-/- mice, but no change in Mrp2 mRNA expression. Several of these transporters
appear to be coordinately regulated, increasing their expression when the expression of another
member is lowered and most of these studies have been done in liver, kidney and intestine. It is
known that the CP expresses a number of transporter proteins, including Mrps. Despite the recent
interest in this highly vascular tissue, little is known about compensatory properties with Abc-type
transporters in the CP.
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1.6 Acetaminophen significance & background
Acetaminophen (N-acetyl-p-aminophenol, APAP) is the most commonly used medication
to treat pain and fever in the United States and Europe. Overdose of APAP accounts for over 50%
of all cases of acute liver failure (ALF) in the U.S. and Great Britain (Hart et al., 1994; Larson et
al., 2005). Extrahepatic organs can be also affected directly or indirectly after APAP overdose.
Of particular significance is the fact that nearly half of overdoses in a meta-analysis of severe
APAP-induced toxicity were unintentional; patients had either taken two separate APAP
preparations simultaneously or used medication combining APAP with narcotics (Larson et al.,
2005). While APAP is generally safe to use at recommended doses, individuals taking in excess
of 4g per day are at risk of hepatocellular necrosis (Ganley et al, 2009). However, many cases
exist in which chronic drug users have developed tolerance to lethal doses of APAP (Rudraiah et
al., 2014; Rudraiah and Manautou, 2016). Interestingly, studies have shown sex-dependent
differences in susceptibility to APAP induced toxicity (Rohrer et al., 2014). In mouse models,
males are more susceptible to APAP induced toxicity;in humans, females have greater rates of
APAP induced toxicity (Rohrer et al., 2014). This difference might affect differentially the drug
metabolism and distribution in men and woman. However, human data may be influenced by
other factors such as alcohol consumption, nutrition, concurrent medication use, and differences
in suicide ideation between sexes. Despite the difference in sex-dependent susceptibility of mice
and humans to APAP, mouse models, especially genetically modified animals, provide a useful
model to study APAP-induced toxicity due to the similar mechanisms of toxicity.
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1.7 APAP metabolism & toxicity
There are three known pathways for APAP metabolism: conjugation with sulfate,
conjugation with glucuronide, and metabolism by the cytochrome P-450 oxidase enzyme system
(Figure 1.5). The first two processes account for most of the metabolism of an ingested dose. The
third process accounts for 5% of the ingested dose and is critical in overdose of APAP. When
APAP is taken in therapeutic doses, glucuronidation and sulfation pathways metabolize ~50% and
~30% of ingested APAP, respectively (Ghanem et al., 2016). The resulting APAP-glucuronide
conjugate is excreted mainly (>75%) into the bile by multidrug resistance-associated protein 2
(Mrp2) and also (<25%) into the plasma by the basolateral efflux transporter Mrp3. The APAPsulfate conjugate is excreted into the bile by Mrp2 and to a lesser degree by breast cancer-related
protein (Bcrp1), and is excreted into the plasma by basolateral efflux transporters Mrp3 and Mrp4
(Beger et al., 2015). After glucoronidation and sulfation, the remaining APAP is converted by the
cytochrome P450 (Cyp) suite of enzymes into N-acetyl-p-benzoquinone imine, or NAPQI, the
main toxic metabolite of APAP. Cyp2E1 is known to play a role in APAP biotransformation (Ko
et al., 2017; Yang et al., 2017). Under normal conditions, this potentially dangerous metabolite is
rendered harmless by reduced glutathione (GSH), an antioxidant compound in the liver. However,
when APAP is taken in excess, the glucoronidation and sulfation pathways become saturated, and
the amount and rate of formation of NAPQI are increased, depleting the GSH stores and
outstripping its capability to make new reduced GSH. After the GSH detoxification pathway
becomes fully saturated, NAPQI is free to cause cellular damage. NAPQI then covalently binds
to macromolecules and causes cell death which leads to subsequent liver dysfunction. Though
similar to the liver, the mechanism for acetaminophen induced toxicity in extrahepatic organs,
such as brain and kidneys, is less well understood.
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A number of transporters have been implicated in the response to APAP induced
hepatotoxicity. These include the Mrps and Bcrp, as well as uptake transporters such as the organic
anion transporting polypeptides (Oatps) and the sodium/taurocholate-cotransporting polypeptide
(Ntcp) (Aleksunes et al., 2005). The role of transporters in the response to APAP induced
hepatotoxicity has been studied at some length, and researchers have discovered that there is a
coordinated decrease in expression of uptake transporters and increase in expression of efflux
transporters, possibly a response to increase the rate at which toxic metabolites are removed from
cells. Aleksunes et. al. (Aleksunes et al., 2005) showed decreases in expression of basolateral
uptake transporters responsible for the transfer of chemicals from the blood to hepatocytes such as
Oatp1a1, Oatp1b2, and Ntcp and also an increase in the expression of basolateral (Mrp3 & 4) and
canalicular (Mrp2) efflux transporters. However, these uptake transporters do not facilitate entry
of APAP into cells. Instead, APAP enters cells through diffusion (Aleksunes et al., 2005).
Additionally, the upregulation of the Mrps occurs after APAP and its metabolites were fully
cleared from the liver, suggesting that this upregulation could be an attempt to protect the liver
from for another toxic APAP challenge rather than an attempt to clear metabolites (Maher et al.,
2005).

1.8 Role of Nrf2
Nrf2 is a transcription factor that plays a multifaceted role in the cytoprotective response
to oxidative stress. Under normal conditions, Nrf2 is sequestered in the cytosol by Kelch-like
ECH-associated protein 1 (Keap1) via its N-terminal domain and is thusly inactivated (Figure 1.6)
(Bataille and Manautou, 2012). Keap1 is also a part of an ubiquitination-proteasome complex,
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and studies have shown that Keap1 interacts with this complex to form ubiquitination of Nrf2,
which results in proteasome degradation. This process of constitutive proteasome degradation of
Nrf2 is likely the cause of the instability of Nrf2 under basal conditions – it has a half-life of 1530 minutes.

Additionally, the Nrf2-Keap1 complex is conserved in rodents, humans, and

zebrafish, indicating its importance in the response to oxidative stress. When oxidative or
electrophilic stress arises, oxidation of cysteine residues of Keap1 and phosphorylation of Nrf2 by
any one of a number of particular kinases results in the dissociation of Nrf2 from Keap1. Nrf2
then translocate into the nucleus. Nrf2 remains in the nucleus until there is no longer oxidative
stress as its nuclear export signal can be disabled in the presence of ROS. Inside the nucleus, Nrf2
typically heterodimerizes with members of the activator protein 1 family, such as Jun and Fos, and
these complexes bind antioxidant response elements (ARE), which are located in the promoter
region of detoxification genes. Binding of Nrf2-protein complexes to the ARE can either activate
transcription of genes involved in the cytoprotective response, or suppress transcription
(Aleksunes and Manautou, 2007) (Figure 1.6).
The genes that Nrf2 targets includes those involved in a variety of cellular functions such
as drug metabolism, ROS scavenging, GSH homeostasis, and efflux transport pathways. While
decreased expression of these ARE-containing genes leads to greater susceptibility to cytotoxic
damage, elevated expression of these genes has been linked to resilience of tumor cells, particularly
in terms of chemotherapeutic resistance. Specific targets of Nrf2 include NAD(P)H quinone
oxidoreductase 1 (Nqo1), heme-oxygenase 1 (Ho-1), GSH, and the Mrps. Nqo1 is a cytosolic
flavoprotein that functions in the catalysis and detoxification of exogenous and endogenous
chemicals as well as in the response to intracellular oxidative stress by scavenging superoxide and
keeping endogenous antioxidants in the reduced form. Ho-1 is responsible for catalyzing the first
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and rate limiting step in the catabolism of heme, a pro-oxidant, to carbon monoxide, biliverdin,
and free iron. Studies have shown that both Ho-1 and Nqo1 are upregulated in the liver in response
to APAP (Aleksunes and Manautou, 2007). GSH also functions in the antioxidant response by
detoxifying harmful chemicals through either direct binding or enzymatic conjugation (Bataille
and Manautou, 2012).

1.9 CP: A model for active transport
In order to understand the function of transporters in the CP, it is also essential to
understand the basis of the experimental techniques that have been used; so, it is necessary to give
a short explanation of the principles used in studies that use membrane transport. A variety of
alternative techniques have been attempted to study this tissue but the delicate nature of the CP,
that is its small size, and its hard access make this a difficult tissue to work with. The CP can be
isolated from fresh brain and kept viable for several hours. This technique has yielded much
valuable data on the apical uptake from CSF into the CP and has been used extensively by Conrad
Johanson and his group to identify the transport characteristics of this interface (Johanson et al.,
2008). This method does, however, have its limitations, basolateral efflux from the CP to the
vascular spaces might be difficult to achieve without the proper use of specific inhibitor or
competitive inhibitors.
The physiological function of Mrps in brain cells is not well defined due to the broad
substrate specificity of many of the transporters. Fluorescent substrates, confocal imaging and
quantitative image analysis have been used for transport studies and found suitable for analyzing
transport of the OA fluorescein (FL), FL-methotrexate (MTX), and fluo-cAMP (cAMP analog) in
CP tissue (Baehr et al., 2006; Reichel et al., 2010). An example taken from our lab of a confocal
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image of fluorescein transport is shown in figure 1.7. The overlapping substrates among the Mrps
remain a limitation. To overcome this limitation, knockout animal models can be used. The use
of this approach allows us to carry out transport studies in viable, undamaged tissue in real time.
Accumulation of substrates can be measured in different compartments of the cells of WT and
specific transporter knockout mice. Consequently, we will be able to make conclusions about
transport capabilities and transport proteins involved in apical uptake (from the CSF to cells) and
basolateral efflux (from the cells to the blood).
Furthermore, using an Mrp4 knockout model we will study transport mechanisms using
known fluo-labeled substrates to determine the role of Mrp4 and roles of other Mrps in the CP.
Villalobos et al. (Villalobos et al., 2002), using confocal microscopy, demonstrated active, apical
to basolateral transport of the herbicide 2, 4-dichlorophenoxyacetic acid. Previous work has shown
that fluo-cAMP can be used as a fluorescent model compound for studying the role of Mrp4 on
function, substrate and inhibitor specificities in CP (Reichel et al., 2010). Previously, three
different inhibition patterns were found for OAs in intact CP: (i) decreased accumulation of the
fluorescent dye in both compartments, (ii) reduction of fluorescent dye in vascular spaces, but not
epithelial cells, (iii) decreased fluorescent dye in vascular spaces with an increased accumulation
of the fluorescent dye in the epithelial cells (Baehr et al., 2006; Reichel et al., 2007; Reichel et al.,
2010; Villalobos et al., 2002). These inhibition patterns are indicators of inhibition of apical
uptake, inhibition of basolateral efflux from epithelial cells to vascular spaces with comparable
effects on the apical uptake step and domination of inhibition of basolateral efflux versus apical
uptake, respectively. Future investigations of gender dimorphism and in-depth appreciation of
how activity of one transporter can compensate in absence of another will be useful for
understanding of the clearance of Mrp substrates and the maintenance of a balanced CSF.
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1.10 Animal models: Mrp4 and Nrf2 knockout mice:
Since knockout mouse models lacking one or more Abc transporters have been generated,
they have been widely used as tools to experimentally assess the contribution of Abc transporters
in drug and drug substrates transport (Lagas et al., 2009; Leggas et al., 2004; Sivils et al., 2013;
Vlaming et al., 2006). In a study, in which saquinavir, digoxin, and paclitaxel were administered,
drugs accumulated more in Pgp homozygous null fetuses (Mdr1a, Mdr1b) compared to wild-type
fetuses. The Mrp2 deficient mice have an impaired response to amphipathic anticancer drugs in
vivo. Besides P-gp, Mrp1 and Mrp2, Mrp4 also play an important role in drug transport. Studies
have demonstrated that Mrp4 transports endogenous molecules that play key roles in cellular
communication and signaling, including cyclic nucleotides, eicosanoids, adenosine diphosphate,
and conjugated steroid hormones. Other physiologically relevant substrates include folate, bile
acids and glutathione, which are co-transported with bile acids (Table A.3). Several in-vitro studies
have shown the role of Mrp4 in the transport of anticancer drugs (topotecan, MTX) and antiviral
drugs (Chen et al., 2002; Leggas et al., 2004). Furthermore, the development of the Mrp4-/- mouse
model has helped us understand both the physiological and pharmacological roles of Mrp4 in-vivo.
Leggas, et. Al. (Leggas et al., 2004), generated the Mrp4-/- mouse. In general these animals
breed normally with normal litter size and the expected female-male ratio. No abnormalities were
observed in the brain, liver, lung or kidney when examined by microscopic histology. Liver and
renal functions were also within the normal limits (Leggas et al., 2004). A study using Mrp4-/demonstrated that Mrp4 limits the brain penetration of topotecan in two levels; first by preventing
cellular accumulation of topotecan and second by restricting topotecan penetration into the brain.
Although the major focus of our research is on Mrp4, we explored the expression of other
Mrps and also several detoxifying /antioxidant enzymes. Nrf2, which is a transcription factor that
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plays a critical role in the cellular defenses against oxidative stress, is known to target most of
these cytoprotective genes in liver (Aleksunes and Manautou, 2007; Aleksunes et al., 2008;
Aleksunes and Klaassen, 2012; Horie et al., 2015; O'Connor et al., 2014; Xu et al., 2005). Nrf2
activators have also been shown to upregulate genes like Pgp, Mrp2 and Bcrp in studies of rat
BBB. The same study showed that in Nrf2-/- mice the upregulation of these three genes was
abolished and their activity was reduced leading to accumulation of substrates. Additionally, Nrf2/-

mice have also revealed that this transcription factor is not the contributing factor for the greater

tolerance of females to hepatoxocants such as APAP (Rohrer et al., 2014).
Furthermore, we have use the Mrp4-/- mouse model to investigated the gender differences
in the blood CSF barrier.

First, we discovered that there are gender differences in some

cytoprotective genes in the mouse CP, Mrp4, Nqo1 and Ho-1. Then, we found that among all the
Mrps we study, Mrp4 was the only one found to be higher in the females compared to males.
Nevertheless, this female higher Mrp4 mRNA expression in CP corresponded to both higher
protein and higher functional activity. In chapter 2 we observed that female have higher Mrp4
expression in CP and accumulate higher cAMP fluorescence intensity in perivascular spaces than
male mice. Later in chapter 3 we explored the effect of a well-known drug induce hepatotoxicant
(APAP) and the effect of the drug in the expression of the Mrps and cytoprotective genes. We
extended our studies to brain tissue excluding the CP (considered blood brain barrier (BBB), where
most of the transporters of our interest are located). Our results indicated that hepatotoxic doses
of APAP increases Abc drug transporters gene expression in male, but not female mouse CP and
brain.
Overall, the findings presented in here have important implications for understanding
efflux transporters in liver and extra-hepatic organs (CP, BBB). Chapter 2 is devoted to gender
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differences in an understudied tissue, the CP (and a physiological role of Mrp4 between male and
female in this tissue). Finally, Chapters 3 showed the effects of the hepatotoxicant APAP and the
influence of this drug in the expression of cytoprotective genes including Mrps in CP and BBB;
and a possible role of the transcription factor Nrf2 in male mouse brain, but not females.

21

Figure 1.1. Localization of blood-brain and blood-CSF interfaces and CP micrographs. The
choroid plexus are highly vascularised epithelial tissue that originates from the ependyma and float
freely in each of the brain ventricles (the two lateral, third and fourth). CP have two major
functions: (1) to act as a diffusion barrier between the blood and the CSF; and (2) to produce and
secrete the CSF that fills the ventricles and subarachnoid spaces. CP micrographs (Emerich et al.
2004).
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Figure 1.2. Anatomy of blood-brain and blood-CSF interfaces. A) The BBB is formed by brain
capillary endothelial cells that are joined together by tight junctions is a selective barrier between
the blood and the brain. B) Blood CSF barrier formed by CP capillaries that are fenestrated and
surrounded by a basement membrane is a selective barrier between blood and CSF (CP image from
Strazielle N. et al. 2000). Together they participate in maintaining stability of neuronal
environment and removal of potentially toxic xenobiotics and metabolic wastes from CSF/brain
to blood for eventual body excretion.
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A)

B)
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Figure 1.3. Schematic diagram of the efflux transport systems for organic anions in the CP.
The uptake of amphipathic organic anions, such as E217βG, taurocholate and estrone sulfate, at
the BBM is mediated by OAT3. The basolateral excretion mechanism for OAs have not been fully
elucidated. Mrp1 is a candidate transporter, but its contribution to efflux of amphipathic-conjugate
metabolites remains controversial. Oatp2 and other Abc transporters, such as Mrp4 and Mrp5, are
alternative transporters for basolateral excretion (Modified from Kusuhara and Sugiyama, 2004).
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Figure 1.4. Schematic diagram of the efflux transporters at the blood-brain barrier.
Localization of efflux transporters at the BBB. The presence of these transporters in luminal and
abuminal membranes in this diagram have been demonstrated at mRNA and protein levels
(Modified from Kusuhara H. and Sugiyama Y., 2005)
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Figure 1.5. Schematic of APAP metabolism by the hepatocyte. At therapeutic doses,
the majority of APAP is metabolized in the liver by glucuronidation and sulfation (Heard, 2008).
Only a small percent of APAP is metabolized in the liver by cytochrome P450 enzymes, mainly
by Cyp2e1 to a toxic reactive metabolite N-acetylp-benzoquinone imine (NAPQI) (Dahlin et al.,
1984) which is safely inactivated by GSH. At toxic doses of APAP, glucuronidation and sulfation
pathways become saturated and more of the reactive metabolite is generated depleting rapidly
pools of GSH (Chen et al., 2003). Unbound NAPQI can bind to macromolecules causing cell death.
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Figure 1.6. Nrf2 activation upon oxidative stress. Under normal conditions, Nrf2 is sequestered
in the cytosol by Kelch-like ECH-associated protein 1 (Keap1) and undergoes to proteosomal
degradation. When oxidative or electrophilic stress arises, Nrf2 dissociates from Keap1. Nrf2
then translocate into the nucleus and binds to antioxidant response elements (ARE), which are
located in the promoter region of detoxification genes. Binding of Nrf2-protein complexes to the
ARE can either activate transcription of genes involved in the cytoprotective response, or suppress
transcription.
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Figure 1.7. Typical fluorescence activity of FL in mouse choroid plexus. A) Confocal
microscope image of WT male lateral CP incubated with 1μM of FL for 45 minutes and B) the
transmited light image. This was a feasibility study showing accumulation of OATP substrate
fluorescein (FL). FL was incubated for 45 minutes and then image in the confocal microscope.
The CP was incubated with the fluorescence substrate in an artificial CSF bath. The movement of
FL can be seen and measure in different compartments (cells, vascular spaces and background).
The FL is also concentrative, having the higher intensity in the vascular spaces, than in the cells.
The background fluorescence intensity is always substracted in the analysis.
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CHAPTER 2
CHAPTER 2. Gender-Specific Expression of ATP-binding Cassette (Abc) Transporters and
Cytoprotective Genes in Mouse Choroid Plexus

2.1 ABSTRACT
The choroid plexus (CP) and blood-brain barrier (BBB) control the movement of several drugs
and endogenous compounds between the brain and systemic circulation. The multidrug resistance
associated protein (Mrp) efflux transporters form part of these barriers. Several Mrp transporters
are positively regulated by the transcription factor nuclear factor erythroid-2-related factor (Nrf2)
in liver. The Mrps, Nrf2 and Nrf2-dependent genes are cytoprotective and our aim was to examine
basal gender differences in expression of Mrp transporters, Nrf2 and Nrf2-dependent genes (Nqo1
and Ho-1) in the brain-barriers. Previous studies have shown higher expression of Mrp1, Mrp2
and Mrp4 in female mouse liver and kidney. We hypothesized that similar renal/hepatic genderspecific patterns are present in the brain-barrier epithelia interfaces. qPCR and immunoblot
analyses showed that Mrp4, Ho-1 and Nqo1 expression was higher in female CP. Mrp1, Mrp2 and
Nrf2 expression in the CP had no gender pattern. Female Mrp1, Mrp2 and Mrp4 mouse brain
expressions in remaining brain areas, excluding CP, were higher than male. Functional analysis of
Mrp4 in CP revealed active accumulation of the Mrp4 model substrate fluo-cAMP. WT female
CP had 10-fold higher accumulation in the vascular spaces than males and 60% higher than Mrp4/-

females. Probenecid blocked all transport. Methotrexate did as well except in Mrp4-/- females

where it had no effect, suggesting compensatory induction of transport occurred in Mrp4-/-.
Collectively, our findings indicate significant gender differences in expression of Mrp transporters
and cytoprotective genes in the CP and BBB.
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2.2 INTRODUCTION
Gender can be an important factor in drug and xenobiotic toxicity through differences in
absorption, metabolism, distribution, and excretion. Many of the genes associated with these
processes have gender-specific patterns in liver and kidney. For example, multidrug resistanceassociated protein 4 (Mrp4/Abcc4) is a membrane transport ATPase expressed at much higher
levels in female than in male murine kidney and liver (Cheng et al., 2008; Lu and Klaassen, 2008).
Its transported substrates include chemotherapeutic drugs, antiretroviral agents, and anti-cancer
agents, as well as several endogenous ligands, such as uric acid, conjugated bile acids,
glucuronidated estrogens, and leukotrienes. Mrp4, together with several other efflux transporters,
is not only associated with cellular resistance to the toxicity of short-term exposure to, for example,
methotrexate (MTX) (Chen et al., 2002; Hooijberg et al., 1999), but it also facilitates transepithelial
transport and excretion by liver and kidney (Chen et al., 2002; Hooijberg et al., 1999; Reichel et
al., 2007). Thus, the effectiveness of certain drugs as well as the excretion rate of xenobiotics and
endogenous metabolites may be significantly impacted by gender. Sex differences in the gene
expression of these efflux transporters may influence both tissue specific and whole body substrate
clearance and, thus, aid in risk assessment and drug dosing decisions.
Efflux transporters are a critical component of the active barrier functions of the bloodbrain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB) as they protect the brain from
endogenous and exogenous compounds, including a variety of therapeutics, by exporting them
from the cerebrospinal fluid (CSF) or brain parenchyma interstitial space (IS) to the blood for
ultimate excretion. The choroid plexus (CP) epithelium (BCSFB) and the brain parenchyma
capillary endothelium (BBB) exert significant control over what goes into and comes out of the
central nervous system. The CP is a highly vascularized epithelium that receives as much blood
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as the rest of the brain combined and secretes about 80% of the CSF. Because it assists in the
clearance of various soluble compounds such as organic anions (OA) from CSF it is referred to as
the “kidney” of the brain. The BBB has an important role as well in controlling movement of
substrates between the blood and the brain IS. These barriers are highly active, dynamic and
selective; however, the gender-specific characterization of the ATP binding cassette (Abc) efflux
transporters in the brain is still limited.
The Abc-type transporters act as gatekeepers by allowing or limiting the entrance of an
enormous variety of substrates across cellular membranes. In CP epithelium, Mrp1, Mrp4 (Leggas
et al., 2004) and Mrp5 (Abcc5) (Roberts et al., 2008) are located in the basolateral membranes –
an orientation that allows active transport from cytosol to an interstitium contiguous with the CP’s
fenestrated capillaries - whereas Mrp2 (Abcc2) is located in the apical membrane – transporting
from cytosol to CSF. Mrps are also located in BBB endothelium of several species, including
humans, rats and mice (Leggas et al., 2004; Rao et al., 1999; Roberts et al., 2008). P-glycoprotein
(P-gp/Abcb1), breast cancer resistance protein (Bcrp/Abcg2), Mrp1, Mrp2, Mrp4 and Mrp5 are all
localized to the BBB luminal membranes. In relatively lower amounts the Abc transporters are also
expressed in astrocytes, microglia, neurons, and oligodendrocytes (Ballerini et al., 2002;
Berezowski et al., 2004).
In addition to Mrps, several drug metabolizing enzymes are expressed in the CP and BBB
including glutathione S-transferases and several isoforms of the cytochrome P450 family
(Decleves et al., 2011; Miksys et al., 2000; Tyndale et al., 1999). There are transcription factors
known to positively regulate the expression and activity of several cytoprotective genes during
periods of oxidative stress. For example, the transcription factor Nrf2 is involved in many cellular
functions including drug metabolism, oxidative stress mitigation and regulation of efflux
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transporter pathways. These genes include NAD(P)H quinone oxidoreductase 1 (Nqo1), hemeoxygenase 1 (Ho-1) and glutamate cysteine ligase catalytic subunit (Gclc), as well as certain efflux
transporters such as Mrp4 (Aleksunes et al., 2008; Aleksunes et al., 2010). Biotransformation of
foreign compounds via these phase I and II enzymes can result in metabolites which can be
transported by Mrps. Consequently, metabolic enzymes and transporters can act together to
eliminate harmful compounds from the brain to the blood for eventual body excretion. The extent
to which metabolism contributes to the BCSFB and to the BBB remains to be established.
Furthermore, the gender-specific patterns of detoxification enzyme profiles and the influence of
Nrf2 on transporter expression have not been well characterized in CP.
There are numerous reports of sexual dimorphism of Abc-type transporters in kidney and liver of
adult mice, rats and humans (Cheng et al., 2008; Lu and Klaassen, 2008), but data on sex
differences in CP are extremely limited. Our primary goal was to test the hypothesis that Abc
transporters and cytoprotective genes in adult mouse CP share kidney- and liver-like gender
expression patterns. Here, gender specific expression patterns of several key cytoprotective genes
and proteins in the CP and brain are presented together with functional data for Mrp4.

2.3 MATERIALS AND METHODS

2.3.1. Animal tissue collection.
All animal studies were performed in accordance with institutional regulations for animal
protection and were approved by the Institutional Animal Care and Use Committee of the
University of Connecticut (Protocol A12-050). Age-matched male and female C57BL/6J mice
(10-12 weeks of age) were purchased from Jackson Laboratory (Bar Harbor, ME, USA). Mrp4-/39

mice with a C57BL/6J background were kindly provided by Dr. John Schuetz from St. Jude’s
Children’s Hospital, Memphis, TN. A colony of these mice is maintained at the University of
Connecticut. All mice were housed in temperature, light, and humidity controlled conditions
approved by the Association for Assessment and Accreditation of Laboratory Animal Care. All
mice were provided standard laboratory chow (Harlan) and water ad libitum. Following euthanasia
via decapitation, brains were removed and immersed in ice-cold PBS. The two lateral CPs of each
animal were removed from the ventricles under a dissecting microscope. Tissues were then
transferred into 0.5 ml tubes containing either RNA later (Qiagen, Valencia, CA, USA), neutral
phosphate buffered 10 % formalin fixative or Laemmli sample buffer for future analyses.

2.3.2. Solutions and chemicals.
8- (2- [Fluoresceinyl]aminoethylthio)adenosine- 3', 5'- cyclic monophosphate (FluocAMP) was purchased from Biolog Life Science Institute (Bremen, Germany). This fluorescent
cAMP analogue is highly resistant to metabolic degradation by cAMP-specific phosphodiesterase.
Probenecid and methotrexate (MTX) were purchased from Sigma (St. Louis, MO, USA).
Information on primary and secondary antibodies for immunoblots is listed in Table 1. All other
chemicals were obtained from Sigma.

2.3.3. SDS-PAGE and immunoblotting.
The two lateral CPs from each animal were suspended in 20 µL of Laemmli sample buffer
(2.3 % SDS, 5 % ß -mercaptoethanol, 0.5 % bromophenol blue, 62.5 mM Tris HCL, pH 6.8) and
stored at -20° C. Equal amounts of sample were loaded on 10 % SDS- Polyacrylamide gels and
transferred to polyvinylidene difluoride membranes (PVDF). After transfer, PVDF membranes
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were blocked at 4°C with 5 % nonfat dry milk (NFDM) in PBS containing 0.5 % Tween (PBS-T).
Membranes were incubated overnight with appropriate primary antibodies, except for a loadingcontrol that was incubated for one hour. Standard β-actin controls (anti-β actin; 1:500) were
included to ensure equal loading and for normalization of the target antibody band intensity. A
description of the individual antibody conditions (controls, primaries and secondaries) is provided
in Table 1. All the primary and secondary antibodies where diluted in the same blocking buffer
solution found in Table 1. A species-appropriate peroxidase labeled secondary antibody (SigmaAldrich) was diluted in blocking buffer and incubated with blots for 1 hour. Finally, protein bands
were detected using a chemiluminescence (ECL) kit (Thermo Scientific) according to the
manufacturer’s instructions prior to exposure to medical x-ray film (Fujifilm). Densitometry of
detected bands was performed using ImageJ software (NIH) for quantitative analysis.

2.3.4. RNA isolation and Quantitative real time polymerase chain reaction (qRT-PCR).
Total RNA was prepared from ventricular male and female CPs using a Qiagen RNeasy
mini kit (Qiagen, Valencia, CA, USA). A Thermo Scientific Nanodrop was used to measure RNA
concentrations and purity by absorbance readings at 260 and 280 nm. For each sample, first-strand
cDNA was synthesized from 0.5 µg total RNA using the Superscript III First-Strand Synthesis
System (Invitrogen, Carlsbad, CA, USA) in a 20 µl reaction, according to the manufacturer’s
instructions. cDNA reactions were conducted in a PCR Sprint thermocycler (Thermo Electron
Corporation). To control for contaminants, no-amplification-controls (NACs) with no enzyme, and
no-template-controls (NTCs) with no cDNA were included. qRT-PCR was performed on CFX96
touchTM Real-time PCR detection System (Biorad) using SsoFastTM EvaGreen Supermix and a 10
µl reaction volume. Cycling parameters for all reactions were as follows: denaturation at 95° C for
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20 seconds; 40 cycles of denaturation at 95° C for 3 seconds; 30 seconds of annealing and
extension at 60° C. Mouse-specific primer pairs were used for each gene (Table 2). Gene
expression was quantified by the ΔΔCT method (Schmittgen and Livak, 2008), using β-Actin as
our internal control gene.
2.3.5. Transport
For transport studies, fresh lateral CPs were removed and transferred immediately into 12well plates containing an artificial cerebrospinal fluid (aCSF; 103 mM NaCl, 25 mM NaHCO3, 4.7
mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4 x 7H2O, 10 mM glucose, 2.5 CaCl2, at pH 7.4) with
pre-dissolved gases (95 % O2, 5 % CO2). Then, CPs were pre-incubated with or without (control)
modulators of organic anion transport for 30 minutes at room temperature. Probenecid was used
as a standard well known broad spectrum inhibitor for organic anion transporters. MTX was used
as a competitive inhibitor for Mrp4. All incubations were carried out in 12-well plates inside
sealed Ziploc bags under 95 % O2, 5 % CO2 in the dark. After 30 minutes of modulator treatment,
fluorescently labeled substrate was added, and the time to reach steady state fluorescence was
determined. Following each measurement, the Ziploc bags were re-filled with 95 % O2, 5 % CO2,
sealed and returned to darkness. Accumulation of fluo-cAMP, a known Mrp4 substrate, was
measured in cells and in vascular/perivascular spaces with or without 50 μM MTX or 1 mM
probenecid. Viability of the tissue was monitored by morphology and substrate accumulation over
time. After pre-incubation and incubation, fluorescence intensity in the different compartments of
CP was imaged by inverted confocal Leica SP8 DMIRB microscope.
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2.3.6. Confocal imaging
After incubation, CPs were transferred to glass bottomed Teflon chambers and observed on an
inverted confocal microscope under the 20 X objective. Under transmitted light, intact epithelia
were selected as described by Reichel et al., 2010 (Reichel et al., 2010). For each piece of CP,
five areas of undamaged CP tissue were chosen, and confocal images were taken. A 543 nm HeNe
laser was used along with appropriate dichroic and long-pass emission filters. All images collected
had the same settings (offset, inset, pinhole, laser intensity, etc.). The laser intensity did not exceed
1 % of the maximum. Auto-fluorescence and photo bleaching were not detectable. Fluorescence
intensities were measured using the Leica LAS AF 2D Analysis software. All data are reported as
fluorescence intensities after background (bathing media fluorescence) subtraction. Confocal
imaging method used as described previously (Breen et al., 2002; Breen et al., 2004; Miller, 2004;
Reichel et al., 2010) and the glass bottomed Teflon chambers were a kind gift from David Miller
at NIEHS.

2.3.7. Statistical/ Data Analysis.
All experiments were carried out with CP tissue isolated from 4-8 mice. Calculated
intensity values were pooled and presented as mean values ± SEM. Experimental means for basal
mRNA and protein expression in WT groups were evaluated using paired t-tests and significant
differences were assumed if P < 0.05. Group means of WT and Mrp4-/- mice were compared using
one-way ANOVA and Dunnetts post hoc test. Differences were considered statistically significant
when P < 0.05.

43

2.4 RESULTS
2.4.1. Mrp mRNA and protein expression in male and female mouse CP. Quantitative PCR
showed significant gender differences in gene expression of Mrp4 and Mrp5 (Figure 2.6.1A).
Females expressed higher mRNA levels of Mrp4 whereas males expressed higher mRNA levels
of Mrp5. The almost 3-fold higher expression of Mrp4 in female CP is consistent with the reported
expression in murine liver and kidney (Lu and Klaassen, 2008; Maher et al., 2006). Mrp1 and
Mrp2 mRNA expression did not differ significantly in male and female CP.
Similar to mRNA expression, Mrp4 protein expression was twice as high in females
compared to males (Figure 2.6.1B). No significant differences between genders were observed
for Mrp1 or Mrp5. Even though hepatic and renal Mrp1 mRNA and protein expression are
reported to be higher in females (Cheng et al., 2008), we found no significant gender difference in
the CP. The lack of a gender difference in Mrp5 protein expression in CP is consistent with its
expression in the liver.

2.4.2. Nrf2, Ho-1, Nqo1 and Gclc mRNA and protein expression in male and female mouse CP.
Figure 2.6.2A shows the mRNA expression of Nrf2 and several Nrf2 dependent genes in male and
female mouse CP. Ho-1, Nqo1 and Gclc genes were selected because they are known to play a
role in xenobiotic metabolism and oxidative stress, generating possible Mrp-transportable
substrates. Together with Mrp4, they are positively regulated by Nrf2 activation in mouse liver
(Rohrer et al., 2014). Neither Nrf2 nor Gclc gene expression differed significantly with CP gender
(Figure 2.6.2A). However, basal mRNA expression of Ho-1 and Nqo1 were higher in the female
CP with Nqo1 more than double that of males.

44

Consistent with the observed mRNA expression, Ho-1 and Nqo1 protein expression were
significantly higher in female compared to male CP (Figure 2.6.2B). The data are consistent with
the previously reported hepatic expression (Rohrer et al., 2014). Also in agreement with the
mRNA data, no significant gender differences were observed for Gclc and Nrf2 protein expression
in CP (Figure 2.6.2B).
2.4.3. Functional analyses and fluo-cAMP transport characteristics. Of the four Mrps with
known localizations in the CP, only Mrp4 showed significant gender-related differences in protein
expression. To determine whether this difference translated to functional differences in substrate
handling capacity, the active accumulation of the model substrate fluo-cAMP was examined.
Figure 2.6.3A-E shows an example of phase contrast (A and C) and fluorescence confocal images
(B and D) of female mouse CP in the absence (B) and presence (D) of 1 mM probenecid, a
relatively nonspecific organic anion transport inhibitor. Fluorescence intensity is greatest in the
vascular/perivascular spaces (VS). These fenestrated vessels are just beneath the choroidal
epithelium and show outlines of red cells which do not take up the fluo-cAMP. In the linear scan
across the image shown in Figure 2.6.3E the CP epithelial cells seem to maintain fluo-cAMP below
the substrate signal in the CSF. Maximum intensity (increase beyond CSF reading, X) is in the
vascular/perivascular spaces, and uptake is totally blocked by probenecid (Figure 2.6.3C-D).
Figure 2.6.3F shows time dependent fluo-cAMP accumulation into female and male mouse CP
vascular/perivascular spaces from a concentration of 2 µM fluo-cAMP. Fluo-cAMP fluorescence
greater than that of the bathing aCSF was detected in both female and male after 50 minutes and
was at or near steady state between 60 and 110 minutes with males reaching steady state somewhat
earlier than females. Figure 2.6.3G shows that 2 µM fluo-cAMP was well below saturation. All
subsequent measurements of fluorescence intensity reported here were done following exposure
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to 2 µM fluo-cAMP for 90 minutes. Under control conditions fluorescence intensity in the
vascular/perivascular spaces was always higher than in cells or bath, and cellular fluorescence was
always below that of the surrounding bath (data not shown).

2.4.4. Effects of probenecid and MTX on fluo-cAMP transport. The fluorescence intensity of
the vascular/perivascular spaces was much higher in female than in male mouse CP (Figure 2.6.4).
Uptake by male CP was only about 10 % that of females. The accumulation in the
vascular/perivascular spaces of the female was abolished by incubation with 1 mM probenecid
(Figure 2.6.4). Uptake by male CP was not significantly different following treatment with
probenecid. In the Mrp4-/- female mice, CP accumulation averaged about 40 % that of WT female
and was completely blocked by probenecid (Figure 2.6.4). Uptake by male Mrp4-/- CP was lower
than the Mrp4-/- female and also was not significantly different than that following probenecid
treatment.
MTX is a known high-affinity substrate for Mrp4, but it is also transported by several other
Mrps. Our results show that fluo-cAMP transport by WT female CP was completely blocked by
50 µM MTX (Figure 2.6.4, lower panel). Again, accumulation in the female Mrp4-/- was only
about 40 % that of wild type female; however, MTX had no effect on this component of transport
indicating the possibility that a compensatory transport process may have been induced in
knockout mice.
2.4.5. Expression of Mrp1, Mrp2 and Mrp4 in mouse BBB. The BCSFB and BBB act together
as gatekeepers to control the movement of organic anions and protect the brain from harmful
compounds. In whole brain, Abc transporters are located mainly in brain endothelial cells (Roberts
et al., 2008). Mrp1, Mrp2 and Mrp4 are expressed at the luminal membrane, facing the blood. To
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compare the expression of BBB Mrps in female and male mouse, mRNA levels were analyzed
after the removal of the CP. In female mouse brain Mrp1, Mrp2 and Mrp4 mRNA expressions
were at least twice that of males (Figure 2.6.5).
Immunoblots showed that protein levels of Mrp1, Mrp2 and Mrp4 were consistent with the mRNA
expression, and that in every case they were significantly higher in females compared to males
(Figure 2.6.5). Thus, a role in preventing the accumulation of their overlapping and often toxic
substrates may be gender specific at the BBB.

2.5 DISCUSSION
Notably, this work revealed that there is a gender difference in a major Mrp transporter in the
CP consistent with a shared kidney- and liver-like sex expression pattern. Female mice expressed
higher Mrp4 mRNA in CP, and this differential expression corresponded to both higher protein
levels in female CP and gender-dependent functional differences (Summary: Figure 2.6.1). Mrp1
and Mrp2 showed no gender differences in CP, and though males had higher Mrp5 mRNA
expression, protein levels were no different. In addition to the efflux transporters, the present study
indicated gender differences in the CP gene expressions of the electrophile scavenging Nqo1 and
the heme-degradating enzyme Ho-1. Again, female CP had higher basal levels of mRNA and
protein expression compared to male. We observed no differences in the expression of Gclc,
consistent with studies in other tissues (Rohrer et al., 2014). Though the hepatic basal expression
of Nrf2 is reportedly higher in males than females (Rohrer et al., 2014), we found no genderdependent differences in CP.
Leggas et al. (2004) showed that Mrp4 limits brain penetration of substrate drugs and is
expressed in the CP and the BBB; however, they did not report gender differences. In their
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Mrp4-/- mouse study, the Mrp4 substrate, topotecan, was accumulated to 10 times the level of
that in the WT brain. Its location in the CP epithelial basolateral membranes facing the blood
side and in the luminal membranes of the BBB endothelium make Mrp4 especially effective
since it not only can prevent cytotoxicity by blocking the cellular entry of potentially toxic
substrates, it is part of the transepithelial transport of substrates from CSF or IS into blood. These
transporters thus limit CNS accumulation of many therapeutic drugs and endogenous metabolites
(Chen et al., 2002; Leggas et al., 2004; Merrell et al., 2008; Zhang et al., 2004). Given the potential
role for Mrp transport during treatment of CNS disease, it is important to determine the possibility
of gender differences at these barriers. Our studies suggest that Mrp4 function may differentially
affect CNS substrate clearance by female and male mouse CP.
Recent studies reported that in liver Mrp2 and Mrp4 expression can be altered in response
to cellular stress differentially in male and female (Rohrer et al., 2014), but the implications are
not yet understood.

Oxidative stress is thought to contribute to the pathogenesis of

neurodegenerative diseases, therefore enzymes and transporters with anti-oxidant properties can
protect the brain from this fate. Nqo1 is an important enzyme in the detoxification pathways of
reactive quinones and reduces oxidative stress (Hwang et al., 2015; Luo et al., 2015; Merrell et al.,
2008). Ho-1 catalyzes the rate limiting step in heme catabolism and is also widely accepted as
being cytoprotective against several stressors, including electrophiles through the production of
bilirubin, a powerful antioxidant and Mrp4 substrate (Luo et al., 2015; Merrell et al., 2008). Gclc
is the rate limiting enzyme in GSH biosynthesis, and GSH conjugates can be Mrp4 substrates. Our
data demonstrate clear gender differences in the CP for the antioxidant genes Nqo1 and Ho-1 with
females having higher basal levels of mRNA and protein expression compared to males.
Consistent with studies in other tissues (Rohrer et al., 2014), we observed no basal gender
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differences in the expression of Gclc in CP, and although it has been reported that there is a
somewhat surprisingly higher hepatic basal expression of Nrf2 in males compared to females
(Rohrer et al., 2014), we saw no gender differences in Nrf2 expression in CP. This suggests that
the potential for Nrf2 activation and GSH production are similar in male and female CP.
Given the gender differences reported here in the CP and the overlapping transporter
substrate specificities, we explored the expression of Mrp1, Mrp2 and Mrp4 in the remainder of
the brain and found evidence of gender specific patterns. Based on prior studies, we assumed the
brain Abc transporters are located mainly in BBB endothelium (Roberts et al., 2008; Zhang et al.,
2004). Our studies indicated that Mrp1, Mrp2 and Mrp4 are expressed in a gender specific fashion
at both gene and protein levels in the BBB. Previously it was reported that there were no gender
differences in the mRNA expression of these three transporters in the whole brain homogenates
(Maher et al., 2005). However, we removed the CP and revealed differences at both mRNA and
protein levels in remaining brain.
Wang et al. (2014) showed that sulforaphane activation of Nrf2, and its translocation to the
nucleus in vivo or in vitro, increases Mrp2 and Ho-1 expression in rat and mouse brain capillaries.
Considering the variety of therapeutic drugs that are handled by these efflux transporters,
conditions leading to oxidative stress or chemical activation of Nrf2 could change drug or
xenobiotic penetration into the brain, reducing their efficacy or toxicity. The levels of Nrf2
activation or translocation in females versus males at these CNS barriers remain to be explored.
However, contrary to expectations and consistent with the basal liver Nrf2 expression in a previous
report (Rohrer et al., 2014), in our study basal Nrf2 mRNA and protein expression was not higher
in female CP compared to male CP. The same study revealed that the higher female liver basal
expression of Nrf2 target genes, Nqo1 and Mrp3, did not correspond to the level of Nrf2
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expression. Moreover, other nuclear transcription factors, including peroxisome proliferator–
activated receptor a, aryl hydrocarbon receptor, and c-Jun N-terminal kinase (JNK), have been
recognized as key mediators in the regulation of the expression and activity of many of these
cytoprotective genes (Aleksunes and Klaassen, 2012; Moffit et al., 2006; Xu et al., 2005). The
gender dependence of additional consequences of Nrf2 activation and translocation to the nucleus,
and the role of other transcription factors, at these CNS barriers remains to be determined. Even
though the expression of these Mrps has been studied extensively in both liver and kidney, the
mechanisms behind the gender-specific CP and BBB expression patterns remains poorly
understood.
Although, brain Mrp1, Mrp2 and Mrp4 expression may have an impact on gender-specific
transport of organic anions in BBB, Mrp4 may play a more prominent role in female and male
mouse CP. On a mass basis, CP is reported to have 4-5 times more Mrp4 than kidney (Leggas et
al., 2004). Mrp4 basolateral membrane localization in CP suggests a role in the flux of important
anions from the CSF to the blood and prevention of penetration of toxins to the brain. Studies by
others have clearly shown that cAMP outflow is mediated by multi-specific membrane transporters
belonging to the Abc family (Biondi et al., 2010). The present study further characterized the
function of Mrp4 by examining the efflux of fluo-cAMP in female and male mouse CP. Previous
work in rat CP by Reichel et al., 2010 (Reichel et al., 2010) showed that Mrp4 functions as an ATP
dependent export pump for cAMP. Thus, based on inhibitor specificity and our Mrp4-/- model,
CFS-to-blood transport of fluo-cAMP was significantly reduced in the Mrp4-/- female. This
confirms a strong involvement of Mrp4 in the transport of this substrate. Even though it is likely
that Mrp4 plays an important role in the transport of cAMP in mouse CP ex-vivo, there might be
other factors in vivo that could contribute to cAMP transport. For example, depletion of
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intracellular GSH with DL buthionine-(S, R)-sulphoximine leads to decreased export of cAMP
and corresponding increases in intracellular cAMP accumulation (Lai and Tan, 2002).
In our experiments, MTX did not affect the transport of fluo-cAMP in female Mrp4-/- CP
suggesting that there are compensatory changes in organic anion transport capacity when Mrp4 is
not present. The Mrp4-/- mice are healthy and have a normal life span (Leggas et al., 2004). Mrp1
through Mrp5 also confer resistance to various anticancer drugs including MTX (Chen et al., 2002;
Russel et al., 2008); therefore, this type of compensation might be attributed to an unidentified
organic anion transporter that is not sensitive to MTX.
Consistent with previous studies, fluo-cAMP proved to be a good substrate model to study
Mrp4 function. Compared with other Mrps, Mrp4 has a higher affinity for cAMP (Chen et al.,
2002). In-vivo cAMP may be involved in intercellular signaling and the physiological contribution
of Mrp4 to the regulation of cyclic nucleotide signaling will need to be further examined.
Mrp gender differences in the CP and brain correlate with the gender differences found in
liver and kidney. The wide distribution of these transporters in combination with the differences
in tissue-specific expression patterns and substrate specificity make them of great interest with
respect to different classes of therapeutics and xenobiotics. The regulation of Mrp expression and
activity by endogenous metabolites, signaling compounds, including sex hormones, and
pharmaceutical agents have been documented.

In gonadectomized mice, 17β-estradiol

replacement markedly stimulates the expression of Mrp3 in both male and female mouse kidney.
5α-dihydroxytestosterone treatment suppressed female-predominant Mrp4 expression (Maher et
al., 2006). In addition, gender can profoundly influence relative toxicity. For example, male mice
are more susceptible to APAP nephrototoxicity than female mice (Hoivik et al., 1995). CYP2E1
is involved in the bioactiviation of APAP in the kidney. Previous studies have shown that higher
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renal CYP2E1 expression in male kidney contributes to greater susceptibility to APAP induced
renal toxicity compared to female mice (Hoivik et al., 1995; Mazer and Perrone, 2008). Our data
on the CP gender differences may provide a further step toward better understanding the impact
of drugs and other organic metabolites on the brain.
In summary, we show here that basal expressions of the Mrps and several antioxidantrelevant genes are higher in females compared to males. Although our experiments show gender
differences in the expression of several of these genes, the mechanism remains unknown. The
present results highlight significant gender differences in the transport of the Mrp4 substrate fluocAMP. The physiological contribution of Mrp4 to regulation of cyclic nucleotide signaling will
need to be further examined. Our results provide some guidance in this matter and suggest that the
movement of endogenous/ exogenous molecules between plasma and brain compartments may be
gender dependent. Because Mrp4 is important in determining the disposition of anionic drugs, and
as a consequence, in determining the pharmacological and/or adverse effects of substrate drugs,
gender differences should be considered in the future.
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2.6 FIGURE LEGENDS AND FIGURES

Figure 2.6.1. Summary of Abc-type transporter mRNA/protein expression in blood brain
interfaces. Known localization of drug transporter expression at the choroid plexus (A-B) and the
blood brain barrier (C-D). Mrp5 and Mrp6 efflux transporters (Mrp5-6? symbol) localization in
the mouse CP remains to be determined due to lack of working antibodies. Green cAMP symbols
indicate that fluo-cAMP accumulation is highest in vascular/subepithelial spaces in females
compared to males. CSF and TJ represents cerebrospinal fluid and tight junctions, respectively.
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Figure 2.6.2. Multidrug resistance-associated proteins (Mrp) 1, 2, 4 and 5 mRNA expression
and immunoblot analyses in wild-type female and male mouse CP. Gene expression or protein
expression was normalized to housekeeping gene β-actin. (A) Relative mRNA expression of Mrp1,
2, 4, and 5. (B) Individual blots with corresponding β-actin together with a summary of relative
protein expressions. The corresponding reference β -actin is found below each target protein,
except for Mrp2 which was detected along with Mrp5. Each column represents an individual
mouse lateral CP. The data are presented as means ± SE (n=4, qPCR; n =8, immunoblots).
Asterisks (*) represent a statistical difference between female and male (p ≤ 0.05).
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Figure 2.6.3. mRNA and protein expression of Nrf2 and Nrf2-regulated Ho-1, Nqo1 and Gclc
in unstressed WT male and female mouse CP. Gene or protein expression was normalized to
housekeeping gene β-actin. (A) Relative mRNA expression of Nrf2, Ho-1, Nqo1 and Gclc. (B)
Individual blots with corresponding β-actin together with a summary of relative protein
expressions. The data are presented as means ± SE (n=4, qPCR; n =8, immunoblots). Asterisks
(*) represent a statistical difference between female and male (p ≤ 0.05).
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Figure 2.6.4. Time course and concentration-dependent fluorescence intensity of fluo-cAMP
in female and male mouse CP. Representative phase contrast (A and C) and confocal (B and D)
images of freshly isolate female mouse CP incubated with 2µM fluo-cAMP at steady state. CP
incubated with fluo-cAMP in the presence (D) or absence (B) of the inhibitor probenecid (1mM).
Confocal and transmitted light images are isolated from different female mice. (E) Plot of
maximum fluorescence intensity (X) in vascular/perivascular spaces of corresponding
representative image. Background intensity was subtracted. (F) Time course of fluo-cAMP
transport (2µM) shows that steady state was reached after 60 minutes in male and continued 110
minutes after. In female fluo-cAMP transport (2µM) shows that steady state was reached after 85
minutes

and

continue

110

minutes

after.

Female

fluorescence

accumulation

in

vascular/perivascular spaces exceeded male fluorescence. Cellular fluorescence was lower than
the bath in all experiments. (G) Saturation of fluo-cAMP transport in control group (female mouse
CP) was directly affected by concentration of fluo-cAMP. The 2µM fluo-cAMP shows
fluorescence intensity below saturation but high enough to be detected and was used for all
functional assays. Scale bar in images A-D represents 25 µm.
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Figure 2.6.5 Effect of standard organic anion inhibitor, probenecid, and competitive
inhibitor, methotrexate (MTX) on fluo-cAMP transport in female and male mouse CP.
Quantification of fluorescence intensity of A) WT and Mrp4-/- Female and male mouse CP
incubated with or without probenecid (1mM) and B) CP incubated with or without MTX (50 µM).
WT females show higher accumulation of fluo-cAMP than WT males and higher than Mrp4-/females. When incubated with the standard inhibitor for organic anion transporters, probenecid,
accumulation of fluorescence was abolished in all groups. MTX significantly reduced fluorescence
accumulation of fluo-cAMP in females. The fluorescence accumulation in VS/PVS was not
affected by MTX. The fluorescence was measured in the vascular/perivascular spaces and
background fluorescence was subtracted. Data are presented as the mean values of 3 animals per
group and the variability is shown as ±S.E. Groups with different letters are statistically different
from each other (p < 0.05). Groups with same letter are not statistically different.
PVS=perivascular spaces, VS=vascular spaces, aCSF= artificial cerebrospinal fluid.
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Figure 2.6.6. qPCR and immunoblot analysis of multidrug resistance associated proteins 1,
2, and 4 in WT female and male mouse brain. mRNA and protein expression were normalized
to β-actin and to control (female mice). (A) Quantification of mRNA and (B) relative protein
expression of the selected efflux transporters in brain. The data are presented as means ± SE (n=4,
qPCR; n =4, immunoblots). Asterisks (*) indicate a statistical difference between female and male
(p≤0.05).
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Figure 2.6.7. Diagram of the route of transport in transport studies. Diagram is a
representation of CP different compartments. Fluo-cAMP is a well-known substrate of Mrp4 and
it is used as our fluorescence model. In our model, we are expecting that the substrate moves from
the CSF to the inside of the cell (black arrow 1) to the perivascular spaces (black arrow 2). The
fluorescence intensity can be measured with confocal microscopy inside cells and/or perivascular
spaces, background fluorescence is always subtracted.
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2.7. Chapter 2 tables
Table 2.7.1. Description of primary and secondary antibodies for immunoblots

NFDM, non-fat dry milk

Protein

Mrp1

Mrp2

Mrp4

Mrp5

Nrf2

Gclc

Ho-1

Nqo1
β-actin

Primary
Antibody
Conc.
Tm/T
ab24102
1:500

Primary
Antibody
Source

Molecular 2⁰ Antibody
weight
Conc.
(kDa)
Tm/T

Abcam

190

ab3373
1:500
4˚C/ ON
ab15602
1:500
4˚C/ ON
ab24107
1:500
4˚C/ ON
8882S
1:500
4˚C/ ON
1:10000
4˚C/ ON
SPA-895
1:5000
4˚C/ ON
ab2346
1:1000
4˚C/ ON
ab8227
1:3500
4˚C/ 1hr

Abcam

190

Abcam

160

Abcam

160

Cell Signaling ~100

Washington

~75

Stressgen
Bioreagents

~33

Abcam

~32

Abcam

42

Anti-ratS
1: 2000
RT/ 1hr
Anti-mouseS
1:2000
RT/ 1hr
Anti-ratS
1:2000
RT/ 1hr
Anti-ratS
1:2000
RT/ 1hr
Anti-ratS
1:2000
RT/ 1hr
Anti-rabbitS
1:20000
RT/ 1hr
Anti-rabbit
1:2000
RT/ 1hr
Anti-goatS
1:10000
RT/ 1hr
Anti-rabbitS
1:2000
RT/ 1hr

Primary and
secondary
blocking buffer
solution
5 % NFDM

5 % NFDM

5 % NFDM

5 % NFDM

5 % BSA

5 % NFDM

5 % NFDM

5 % NFDM

5 % NFDM

BSA, bovine serum albumin
S
Antibody purchase from Sigma
Con, Antibody concentration
Tm, incubation temperature
T, incubation time
ON, overnight
RT, room temperature
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Table 2.7.2. Primer sequences for quantitative real-time-PCR
Gene name

Gene symbol

Primer forward and reverse sequences

Actin, beta

Actb

R: 5’-GCA GAC AGC CAA GGA GCC CAA AGA CC-3’
F: 5’-GCA ACG AGC GGT TCC G-3’

Glyceraldehyde-3-phosphate

Gapdh

F: 5’-GACAACTTTGGCATTGTGGAAGGG-3’
R: 5’-TGGATGCAGGGATGATGTTCTGG-3’

Abcc1

F: 5’-TTCGGAAGGGAGAATCGGCTTCAA-3’
R: 5’-TGTTCAGTGCACCTTGCTTGTTCG-3’

Abcc2

F: 5’-TCC AGG ACC AAG AGA TTT GC-3’
R: 5’-TCT GTG AGT GCA AGA GAC AGG T-3’

Abcc4

F: 5’-TAATGGAAGCAGACAAGGCCCAGA-3’
R: 5’-AGAGGCCAGTGCAGATACATGGTT-3’

Abcc5

F: 5’-ACA GCC GCT ATG GAC ACA GAG ACA GA-3’ R: 5’-AGG
CGA AGT TTC AGC AGG ACA GGA TG-3’

Nrf2

F: 5’-TCT ATG TGC CTC CAA AGG-3’

dehydrogenase
ATP-binding cassette, subfamily C (Mrp), member 1
ATP-binding cassette, subfamily C (Mrp), member 2
ATP-binding cassette, subfamily C (Mrp), member 4
ATP-binding cassette, subfamily C (Mrp), member 5
Nuclear factor erythroid 2-

R: 5’-CTC AGC ATG ATG GAC TTG GA-3’

related factor 2
NAD(P)H quinone

Nqo1

dehydrogenase 1
Heme oxygenase 1

F: 5’-TTT AGG GTC GTC TTG GCA AC-3’R: 5’-GTC TTC TCT GAA
TGG GCC AG-3’

Ho-1

F: 5’-GAGCCTGAATCGAGCAGAAC-3’
R: 5’-CCTTCAAGGCCTCAGACAAA-3’

Glutamate--cysteine ligase
catalytic subunit

Gclc

F: 5’-CTGCACATCTACCACGCAGT-3’
R: 5’-TTCATGATCGAAGGACACCA-3’
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CHAPTER 3
CHAPTER 3: Gender-dependent expression of cytoprotective genes at blood-brain interfaces in
response to acetaminophen
3.1. ABSTRACT
The choroid plexus (CP) and blood-brain barrier (BBB) are both portals and barriers for the
movement of many drugs and metabolites between the brain and systemic circulation. Gender
differences in drug conjugation and excretion can affect therapeutic and toxic responses. Certain
multidrug resistance associated protein transporters (Mrp4) and nuclear factor erythroid-2-related
factor (Nrf2)-regulated stress genes (NAD(P)H quionine oxidoreductase-1, Nqo1; heme
oxigenase-1, Ho-1) are higher in female than in male mouse CP; and Mrp1, Mrp2 and Mrp4 are
higher in the BBB of females as well. Male mice are known to be more susceptible to
acetaminophen (APAP; 400 gm/kg) induced hepatotoxicity perhaps due to reduced expression of
cytoprotective genes. Our aim was to examine gender differences in the response of these genes
in lateral CP and brain (with the lateral CP removed) 24 h after an hepatotoxic dose of APAP in
wild-type (WT) and Nrf2-/- mice. We also ascertained the gender-dependent response to APAP of
Cyp2e1, an enzyme responsible for the bioactivation of APAP to reactive intermediates and
expressed equivalently in WT males and females. APAP treatment enhanced the gene expression
of Nrf2, Mrp2, Mrp4, Nqo1, Cyp2e1 and Gclc in brain of WT males. In contrast, brain expression
of Mrp2, Mrp4, Nqo1, Ho-1 and Gclc were reduced in Nrf2-/- male mice following APAP. No
changes were observed in the brains of either genotype of female mice. In the CP, Nrf2, Nqo1 and
Ho-1 were enhanced in WT male mice following APAP, but Cyp2e1 and Gclc were unchanged.
Nqo1, Ho-1, Gclc and Cyp2e1 levels of expression were also unchanged in Nrf2-/- CP. However,
Nrf2-/- females exhibited higher CP mRNA expression of Cyp2e1 and Nqo1 following APAP.
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Together, the data suggest that gender dependent expression of stress response genes (Nqo1 and
Ho-1) and Mrps at blood-brain interfaces may influence the potential neurotoxicity of APAP
differentially in males and females.

3.2. INTRODUCTION
The choroid plexus epithelium (CP) is the blood-cerebrospinal fluid barrier (BCSFB) and, together
with the blood brain barrier (BBB, capillary endothelium), contains numerous selective transport
processes that regulate the movement of fluid, nutrients, hormones, etc., and potentially deleterious
compounds and their metabolites into or out of the CFS and brain interstitial space (IS). Important
contributors to the barrier function of CP and BBB are the ATP binding cassette (Abc)-type
multidrug transporters that mediate drug resistance by energy-dependent drug efflux from cells
and by influencing the pharmacokinetics of substrate drugs through directional transport across
the epithelial membranes in the body (Reichel et al., 2010). These multidrug resistance proteins
(Mrp) are membrane transporters expressed differentially in the liver, kidney, intestine, brain, and
other tissues. Mrp1 and 4 are localized in the basolateral membranes (Gao et al., 1999; Leggas et
al., 2004) while Mrp2 is located in the apical membranes of mouse CP (Roberts et al., 2008). Mrps
are also distributed across the entire brain, primarily expressed in BBB endothelium of humans,
rats and mice (Leggas et al., 2004; Rao et al., 1999; Roberts et al., 2008) with lower amounts found
in astrocytes, microglia, neurons, and oligodendrocytes (Ballerini et al., 2002; Berezowski et al.,
2004). The efflux transporters Mrp2 and Mrp4 are localized to the BBB luminal membranes
(Roberts et al., 2008). Abc-type transporters are capable of pumping a wide variety of substrates
out of the cell including chemotherapeutic drugs and antiretroviral agents, anti-cancer agents, as
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well as several endogeneous ligands, including uric acid, conjugated bile acids, glucuronidated
estrogens, and leukotrienes (Russel et al., 2008; Tekenaka et al., 2007; Zhou et al., 2008).
A number of transporters have been implicated in the response to acetaminophen (APAP)
induced hepatotoxicity. APAP is a widely used over the counter drug that is safe to take at
therapeutic doses, but overdose is one of the leading causes of acute liver failure. APAP is
primarily metabolized by glucuronidation and sulfation (McGill and Jaeschke, 2013). A small
percent of APAP is converted into the reactive intermediate n-acetyl-p-benzoquinone imine
(NAPQI) by cytochrome P450 (CypE1) which can be detoxified by glutathione. The APAPglucuronidate conjugate is excreted mainly (>75%) into the bile by Mrp2 and also (<25%) into the
plasma by the basolateral efflux transporter Mrp3 (McGill and Jaeschke, 2013). The APAP-sulfate
conjugate is excreted into the bile by Mrp2 and to a lesser degree by breast cancer-related protein
(Bcrp1), and is excreted into the plasma by basolateral efflux transporters Mrp3 and Mrp4 (Beger
et al., 2015). At toxic doses, the main pathways (glucoronidation and sulfation) are saturated and
an excess of NAPQI is produced, rapidly depleting glutathione. Unbound NAPQI then covalently
binds to macromolecules and causes cell death and subsequent liver dysfunction. Previous studies
have reported that acetaminophen generates free radicals through this NADPH oxidase activity in
hepatocytes (Letelier et al., 2011), but acetaminophen also increases the rate of reactive oxygen
species (ROS) production in brain in a dose-dependent manner (Posadas et al., 2010). The high
level of ROS depletes glutathione, and acetaminophen-induced oxidative stress causes
neurotoxicity (Posadas et al., 2010). Though likely similar to the liver, the mechanism for
acetaminophen induced toxicity in extrahepatic organs, such as brain and kidneys, is less well
understood.
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The expression of several Mrp efflux transporters is regulated by Nrf2 via Nrf2-mediated
responses to oxidative stress (Aleksunes et al., 2008).

Under normal conditions, Nrf2 is

sequestered in the cytosol by Kelch-like ECH-associated protein 1 (Keap1) via its N-terminal
domain and is thereby inactivated (Bataille and Manautou, 2012). When oxidative or electrophilic
stress arises, Nrf2 dissociates from Keap1 and translocates into the nucleus. Inside the nucleus,
Nrf2 typically heterodimerizes with members of the activator protein 1 family, such as Jun and
Fos, and these complexes bind antioxidant response elements (ARE) which are located in the
promoter region of detoxification genes. Binding of Nrf2-protein complexes to the ARE can
activate transcription of several genes involved in the cytoprotective response (Aleksunes and
Manautou, 2007).
Antioxidant defense genes are partially responsible for protection against drug induced
hepatotoxicity. NAD(P)H quionine oxidoreductase-1 (Nqo1) and heme oxigenase-1 (Ho-1) are
two of the oxidative stress responsive genes that are up-regulated upon activation of Nrf2, which
serves as a cellular sensor for oxidative stress (Aleksunes and Klaassen, 2012; Hwang et al., 2015;
Luo et al., 2015).

Nqo1 acts as a cytoprotectant by catalyzing the reduction of quinones and

semiquinones to relatively stable hydroquinones (Dinkova-Kostova and Talalay, 2010).
Reduction of semiquinones impedes redox cycling and formation of reactive oxygen species.
Hepatocellular damage due to APAP-induced oxidative stress also induces hepatic Ho-1 resulting
in increased antioxidant, bilirubin, but the latter’s role as a modulator of APAP toxicity is less
clear.
It is known that mouse treatment with the Nrf2 activator chemicals oltipraz, ethoxyquin
and butylated hydroxyanisole induces increased hepatic levels of Mrp2–4 mRNA (Merrell et al.,
2008). Furthermore, administration of toxic acetaminophen (APAP) doses to C57BL/6J mice
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generates electrophilic stress and subsequently increases levels of hepatic Nqo1, Gclc and Mrp14. Aleksunes et al. (Aleksunes et al., 2008) showed that APAP treatment of male mice increases
hepatic Mrp3 and Mrp4 mRNA and protein in WT, but not Nrf2-/- male mice. Although, the role
of transporters in the response to APAP induced hepatotoxicity has been studied at some length,
the response to APAP hepatotoxicity in extrahepatic organs is limited.

Ghanem et al., 2015

(Ghanem et al., 2015) showed Nrf2 nuclear levels increased by 58% at 12 h after APAP along with
significant increments in mRNA and protein expression of Nqo1 and Ho-1 in male whole brain
(including CP). In the same study, APAP treated Nrf2 knockout mice did not increase mRNA or
protein expression of Mrp2 and Mrp4 as observed in WT male brains, suggesting that brain
changes in Mrp2 and Mrp4 expression may be due to in situ Nrf2 activation by APAP metabolites.
Although previous work showed sex differences in susceptibility to APAP hepatotoxicity in mice,
i.e., male mice are more susceptible to APAP induced hepatotoxicity than female, the underlying
mechanism(s) remains unknown. Furthermore, no evidence of gender differences in response to
APAP has been reported in the mouse CP or brain.
Gender differences in expression of these cytoprotective entities can affect the
susceptibility to different compounds, as well as how they are processed and handled in the body,
facilitating the generation of secondary cytotoxic compounds. Mrp transporter substrates also
include APAP-glucuronide, APAP-sulfate and APAP-glutathione, metabolites important in APAP
detoxification. The wide variety of substrates handled by Mrps, together with their distribution and
gender dependent expression, contributes to their function in preventing the intracellular
accumulation of these compounds. Additionally, CYPs and antioxidant defense genes that are
abundant in the liver are also expressed in many extra-hepatic tissues including the brain and CP
(Dutheil et al., 2010; Ghosh et al., 2010). Our aim in the present study was to examine gender
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differences in expression of Abc transporters, Nrf2 and related stress genes (NAD(P)H quionine
oxidoreductase-1, Nqo1, heme oxigenase-1, Ho-1 and Gclc) in the brain and CP following an
hepatotoxic dose of APAP. We also analyzed Cyp2e1, an enzyme responsible for the bioactivation
of APAP to reactive intermediates. Gender specific expression of antioxidant defense genes in the
CP and brain in response to drugs like APAP will help us better understand their potential effects
on CNS.

3.3. MATERIALS AND METHODS
3.3.1. Animals and Treatment.
All animal studies were performed in accordance with institutional regulations for animal
protection and were approved by the Institutional Animal Care and Use Committee of the
University of Connecticut (Protocols A12-050 and A15-041). Male and female wild-type (WT)
C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Nrf2-/- (Nrf2knockout) mice with a C57BL/6J background were kindly provided by Dr. Angela Slitt from the
University of Rhode Island. A colony of these mice is maintained at the University of Connecticut.
All mice were housed in temperature, light, and humidity controlled conditions approved by the
Association for Assessment and Accreditation of Laboratory Animal Care.

All mice were

provided standard laboratory chow (Harlan) and water ad libitum. APAP was dissolved in saline
(pH 8.0) and administered by intraperitoneal injection.

WT and Nrf2-/- male and female mice

were fasted overnight prior to treatment with APAP (400 mg/kg, i.p.) or saline. Animals were
sacrificed 24 hours after treatment. Following euthanasia via decapitation, plasma was collected
and brains were removed and immersed in ice-cold PBS. The two lateral CPs of each animal
(referred to hereafter as CP) were removed from the ventricles under a dissecting microscope and
the remaining parts of the brain without CP (referred to hereafter as brain) were snap frozen in
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liquid nitrogen. A portion of the liver was collected and fixed in 10% zinc formalin and the
remaining liver tissue was snap frozen in liquid nitrogen. Frozen tissues were stored at -80°C until
assayed. Pieces of CP and brain were directly transferred into 0.5 ml tubes containing RNA later
(Qiagen, Valencia, CA, USA) for later analyses.

3.3.2. Solutions and chemicals.
All chemicals including APAP were purchased from Sigma-Aldrich (St. Louis, MO).

3.3.3. RNA isolation and Quantitative real time polymerase chain reaction (qRT-PCR).
Total RNA was prepared from male and female CPs using a Qiagen RNAeasy mini kit
(Qiagen, Valencia, CA, USA). Brains were homogenized and RNA was isolated using the Trizol
method. A Thermo Scientific Nanodrop was used to measure RNA concentrations and purity by
absorbance readings at 260 and 280 nm. For each sample, first-strand cDNA was synthesized
from 0.5 µg and 1 µg total RNA, CP and brain, respectively, using the Superscript III First-Strand
Synthesis System (Invitrogen, Carlsbad, CA, USA) in a 20 µl reaction, according to the
manufacturer’s instructions.

cDNA reactions were conducted in a PCR Sprint thermocycler

(Thermo Electron Corporation). To control for contaminants, no-amplification-controls (NACs)
with no enzyme, and no-template-controls (NTCs) with no cDNA were included. qRT-PCR was
performed on CFX96 touchTM Real-time PCR detection System (Biorad) using SsoFastTM
EvaGreen Supermix and a 10 µl reaction volume. Cycling parameters for all reactions were as
follows: denaturation at 95° C for 20 seconds; 40 cycles of denaturation at 95° C for 3 seconds; 30
seconds of annealing and extension at 60° C. Mouse-specific primer pairs were used for each gene
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(Table 1). Gene expression was quantified by the ΔΔCT method (Schmittgen and Livak, 2008)
and normalized to the internal control gene β-actin.

3.3.4. Assessment of Hepatotoxicity: Serum alanine transaminase (ALT) and Histopathology.
Serum ALT activity was determined as a biochemical indicator of hepatocellular necrosis. Infinity
ALT Liquid Stable Reagent (Thermo Fisher Scientific Inc., Waltham, MA) was used according to
the manufacturer’s protocol. Hepatotoxicity was confirmed by histologic examination of liver
tissue sections. Liver samples were fixed in 10% neutral buffered zinc formalin prior to processing
and paraffin embedding. Liver sections (5 micron) were stained with hematoxylin and eosin
(H&E) and examined for histopathological changes by a board-certified veterinary pathologist (Dr.
Kirklyn Kerr). The slides were evaluated for the severity of degenerative and necrotic changes in
the centrilobular regions in both male and female liver samples from both genotypes (WT and
Nrf2-/-) treated and untreated with APAP.

3.3.5. Statistical/ Data Analysis.
All experiments were carried out with CP or brain tissue isolated from 5-6 mice. Calculated
intensity values were pooled and presented as mean values ± SEM. Experimental means for basal
mRNA expression in WT groups were evaluated using paired t-tests and significant differences
were assumed if P < 0.05. Group means of WT and Nrf2-/- mice were compared using one-way
ANOVA and Dunnett’s post hoc test. Differences were considered statistically significant when
P < 0.05.
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3.4. RESULTS
3.4.1. Plasma ALT Activity and Liver Histology in WT and Nrf2-/- mice following APAP. Liver
injury was assessed by plasma ALT levels in male and female mice treated with APAP (400 mg/kg,
i.p.) or vehicle and sacrificed 24 h after dosing. ALT activity was significantly elevated in both
WT and Nrf2-/- male mice following APAP treatment, whereas no increases in ALT were observed
in either genotype of female mice (Figure 3.6.1, A). Numerous studies have shown higher
resistance to APAP toxicity in C57B/J female mice compared to males (Aleksunes et al., 2008;
Du et al., 2014; Lancaster et al., 2015; Rohrer et al., 2014). Histologic examination and grading
of WT female and male liver tissue sections at 24 hours after treatment with APAP confirmed
hepatocellular damage in male, but not female, WT mice. WT male liver sections at 24 hr showed
cellular damage primarily in centrilobular regions (Figure 3.6.1, G and D). No significant damage
was observed in female livers at either time point (Figure 3.6.1, C and E). Treatment with APAP
resulted in significant necrosis in both WT male and Nrf2-/- males, with 50% and 75% more ALT
plasma elevation, respectively, than their female counterparts.

3.4.2. Mrp2, Mrp4, and Nrf2 mRNA expression in male and female WT mouse CP and brain
following APAP. Quantitative PCR showed higher mRNA expression of Mrp2 and Mrp4 in male
brain after APAP treatment but no changes in CP (Figure 3.6.2).

Mrp2, Mrp4 and Nrf2 were

expressed at higher levels in brain of females than males, while only Mrp4 was expressed in a
gender-dependent manner in CP, female higher than male, consistent with prior findings (Flores
et al., 2017). Nrf2 mRNA expression in male brain and CP increased almost 2-fold after APAP
treatment. However, female brain Nrf2 mRNA expression was unchanged by APAP. The
increases in expression of these efflux transporters are consistent with the increases seen in
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hepatocytes after toxic acetaminophen treatment (Aleksunes et al., 2008; O'Connor et al., 2014).
The mechanistic involvement of Mrps in the acetaminophen pathway is unknown. Greater basal
expression of Mrp2, Mrp4 and Nrf2 in female brain may contribute to their lower susceptibility to
APAP toxicity. However, no changes in toxicity in Nrf2-/- female mice suggest that there might be
other transcription factors contributing in to the lower susceptibility to APAP toxicity in the
absence of Nrf2.

3.4.3. Effect of APAP on Mrp2 and Mrp4 mRNA expression in WT and Nrf2-/- male and female
mouse brain. mRNA expression of Mrp2 and Mrp4 was induced by APAP in brain of WT but
not in Nrf2-/- males (Figure 3.6.3). Interestingly, there was a significant reduction in the expression
of these transporters in male Nrf2-/- mice following APAP. No significant change in expression
of either gene was detected between WT and Nrf2-/- female mice after 400 mg/kg dose of APAP.
These two Abc transporters responded to APAP treatment in a gender specific manner in the brain,
probably at the BBB endothelium.

3.4.4. CP and brain mRNA expression of Cyp2e1, Nqo1, Ho-1 and Gclc in male and female WT
and Nrf2-/- mice following APAP. qRT-PCR analysis revealed higher basal expression of Nqo1
and Ho-1 in the female in both CP and brain , but no gender differences in the expression of Cyp2e1
and Gclc in WT mice (Figure 3.6.4). APAP enhanced the expression of Nqo1, Cyp2e1 and Gclc
in male brain but not female. In the CP Nqo1 was enhanced in WT male mice following APAP
while Cyp2e1 and Gclc were unchanged. In contrast Ho-1 was up-regulated in male mouse CP
after treatment with no changes in expression in brain. The latter had lower expression of Nqo1,
Ho-1 and Gclc in Nrf2-/- after APAP administration although their expression in the knockout CP
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was unchanged. Nrf2-/- females exhibited higher CP mRNA expression of Cyp2e1 and Nqo1
following APAP. These results confirm (Flores et al., 2017) that female brain and CP have overall
higher expression of cytoprotective genes compared to males. Also, most of the increases in
cytoprotective gene expression in both CP and brain at 24 h after a 400 mg/kg dose of APAP
occurred in WT males and not in females.

In Nrf2-/- males there were either no changes or

diminished expression of cytoprotective genes in response to APAP.

3.5. DISCUSSION
Collectively, these results indicate that doses of APAP that are hepatotoxic also lead to
alterations in drug disposition and transporter gene expression in male, but not in female mouse
CP and brain. In our previous studies, we reported gender differences in Mrp expression in mouse
CP and BBB consistent with a shared kidney- and liver-like sex expression pattern. Interestingly,
female mice expressed higher Mrp4 mRNA in CP, and this differential expression corresponded
to both higher protein levels in female CP and gender-dependent functional differences in the
transport of an Mrp4 substrate, cAMP (Flores et al., 2017). Among other substrates, Mrp2 and
Mrp4 are also known to transport APAP conjugates and their expression is dependent on the Nrf2
transcription factor (Aleksunes et al., 2005; Aleksunes et al., 2008). As part of the cellular stress
response Nrf2 regulates positively a variety of genes shown to protect against drug induced liver
toxicity following toxic doses of APAP (Aleksunes and Manautou, 2007). The present study
indicated that male and female mouse CP and BBB Mrp2 and Mrp4 mRNA expression responded
differently to an hepatotoxic dose of APAP. In addition to the efflux transporters, we observed
gender-specific changes in gene expressions of the electrophile scavenging Nqo1 and the hemedegradating enzyme Ho-1 at mouse brain interfaces following APAP treatment.
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APAP overdose is known to cause severe hepatotoxicity in animals and humans although
extrahepatic damage is less understood. Gender differences in susceptibility to APAP-induced
hepatotoxicity have been reported, i.e., female mice show greater resistance to APAP-induced
hepatotoxicity than male (Hoivik et al., 1995; Masubuchi et al., 2011; O'Connor et al., 2014; Sheng
et al., 2013).

However, the mechanism underlying the postulated resistance to APAP

hepatotoxicity in female mice remains to be determined. Our study confirmed that female mice
were resistant to the hepatotoxic effects of APAP (400 mg/kg), demonstrated by serum ALT and
histological analysis. Consistent with previous studies, we observed significantly elevated plasma
ALT activity in both WT and Nrf2-null male mice following APAP treatment. No increases in
ALT were observed in either genotype of female mice, lending support to the idea that female
C57BL/6 mice are more resistant to APAP hepatotoxicity; however there are studies that have
reported no sex differences in APAP hepatotoxicity in other mouse strains, for example in CD-1
mice (Hoivik et al.1995), although one may argue that the gender differences in the CD-1 mice
were obscured by a considerably higher APAP dose (600 mg/kg) than that administered in the
present study.
Key initiating events in APAP hepatotoxicity are the formation of the reactive metabolite,
GSH depletion and formation of APAP-protein adducts (Jaeschke et al., 2014). It is known that
Cyp2e1 is expressed in the brain (Ferguson and Tyndale, 2011; Miksys and Tyndale, 2013) and is
the key enzyme responsible for the bioactivation of APAP to reactive intermediates. We found
that this enzyme is expressed equivalently in WT males and females in both brain and CP. Dai et
al., 2006 (Dai et al., 2006) showed that although female C57Bl/6 mice are known to be more
resistant, there are no differences in hepatic metabolic activation of APAP. Here, we found that
Cyp2e1 expression in brain was induced by APAP in WT male mice but not in WT female. The
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induction of this enzyme in male brain suggests that some minor metabolism is occurring in the
brain. Another key enzyme that plays a role in APAP metabolism is Gclc, the rate-limiting enzyme
in GSH biosynthesis (McGill and Jaeschke, 2013). Previous studies have shown that over
expression of Gclc decreases susceptibility to APAP overdose in male mice, but not female,
suggesting that somehow the Gclc-regulated GSH synthesis might be gender-dependent (Botta et
al., 2006). Our data demonstrated that Gclc had no gender-dependent expression in brain;
however, we observed that Gclc mRNA expression was induced in WT male brain following
APAP. Interestingly, brain, but not CP, Gclc mRNA expression decreased in Nrf2-/- after APAP
treatment. No changes were observed in female.
We have previously observed higher expression of Mrp2 and 4 genes in the female BBB
compared to the male (Flores et al., 2017). Here, we have repeated that observation and note,
additionally, that there was higher Nrf2 mRNA expression in female brain. This pattern for Mrp4
and Nrf2 held true for the CP as well. Both CP and brain Nrf2 mRNA expression increased in
WT male following APAP treatment but remained unchanged in WT female (Figure 3.6.3). Nrf2
expression and activation might be tissue specific, and we only observed an APAP-inducible
mRNA expression induction in Mrp2 and Mrp4 in male brain, whereas there were no changes in
CP (Figure 3.6.3). Interestingly, the apical membrane localization of Mrp2 may explain why its
expression does not increase in the CP. Assuming this efflux transporter is capable of pumping
APAP conjugates out of the cell, its apical location would keep these conjugates inside the CSF.
In the case of Mrp4, a basolateral transporter in the CP, the capacity to remove damaging
conjugates to the blood may be complementary to other CP organic anion transporters capable of
transporting APAP conjugates. However, because both Mrp2 and Mrp4 are located in the luminal
membrane of BBB they may work together in this barrier to prevent APAP-conjugates from
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entering the brain IS and (or) removing them to the blood for eventual body excretion. Importantly,
the APAP-induced increase of Mrp2 and Mrp4 transporters in WT males was not observed in Nrf2/-

mice (Figure 3.6.4). The facts that Mrp2 and Mrp4 male Nrf2-/- mouse mRNA expression in

brain was reduced after APAP treatment and these animals showed dramatic liver necrosissuggests
that induction of these Nrf2-dependent genes may also limit APAP toxicity in other tissues
including brain. There were no significant changes in female brain or CP of either genotype
following APAP. These are not unlike the patterns observed in liver following APAP treatment
in males and females (Aleksunes et al., 2008; Rohrer et al., 2014).
The data reported above suggest that transcription factors, other than Nrf2, may be involved
in female responses at brain interfaces to APAP toxicity. However, Nrf2 is known to be a major
regulator of antioxidant genes such as Nqo1, Ho-1 and Gclc that play important roles in APAP
disposition by liver. Both Nqo1 and Ho-1, were higher in female at basal levels, increased in WT
males following APAP treatment, and were reduced in male Nrf2-/- after APAP, whereas there
were no changes in female brain or CP after APAP. This suggests that cytoprotective genes
responded in both a tissue specific and a gender specific manner. These findings support the idea
that brain, mainly BBB, may play a bigger role in APAP metabolism and transport than CP, and
further studies are needed to understand how APAP conjugates are transported in the brain and if
there are gender differences in the transport of the substrates.
In summary, female mouse brain and CP responded differently to an hepatotoxic dose of
APAP than male. Furthermore, our studies with the Nrf2-/- mice strongly indicate that this
transcription factor is not responsible for the resistance of female mice to APAP-induced
hepatotoxicity, suggesting that other mechanisms must contribute to this gender difference. Our
results also demonstrate that mouse female brain and CP have an overall higher basal expression
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of cytoprotective genes compared to males. Interestingly, basal Nrf2 mRNA expression did not
show gender-related differences in CP. In contrast to CP, basal Nrf2 mRNA levels were higher in
female brain compared to male mice, an indication that other regulatory factors may contribute to
the higher basal expression of cytoprotective genes in CP of female mice. Further characterization
of gender-specific expression of antioxidant defense genes in the CP and brain following toxicant
exposure will help us understand potential gender differences in brain drug response.
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3.6. FIGURE LEGENDS AND FIGURES

Figure 3.6.1. Gender differences in APAP hepatotoxicity in mice. Female and male mice were
sacrificed at 24 hours following APAP treatment. (A) Plasma ALT activity in WT and Nrf2-/- mice
following APAP treatment (400 mg/kg). ALT activity was significantly elevated in both WT and
Nrf2-/- male mice following APAP treatment, while no increases in ALT were observed in either
genotype of female mice. (B–I) Histopathology of liver sections (H&E staining). Representative
liver sections from WT and Nrf2-/- mice at 24 hours treated with vehicle or APAP treatment.
Histopathology of tissues confirms ALT results. Arrows indicate cellular damage, localized
primarily in centrilobular regions (asterisks). PT denotes the portal triads. No liver damage is
noted in male or female vehicle treated mice, but high damage is seen in both male genotypes of
APAP treated groups.

Females of both genotypes showed less damage than their male

counterparts. Data are presented as the mean ± S.D. (n = 5 animals). Asterisks (*) show statistical
differences (P < 0.05) between groups, number symbol (#) show statistical differences between
male and female.
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Figure 3.6.2. Mrp2, Mrp4, and Nrf2 mRNA expression in male and female WT mice
following APAP. A) Choroid plexus and B) brain without CP. Mrp2 and Mrp4 mRNA expression
in male brain increased after APAP, but not in CP. Mrp2, Mrp4 and Nrf2 in brain are expressed
at higher levels in females than males, while only Mrp4 is expressed in a gender-dependent manner
in CP. Gene expression was normalized to β-actin. Data are presented as the mean ± S.D. (n = 5
animals). Asterisks (*) show statistical differences (P < 0.05) between groups.
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Figure 3.6.3. Effect of APAP on Mrp2 and Mrp4 mRNA expression in WT and Nrf2-/- male
and female mouse brain (sans CP).

mRNA expression of Mrp2 and Mrp4 was induced by

APAP in brain of WT but not in Nrf2-/- males. No significant changes in expression of either gene
were detected between WT or Nrf2-/- female mice after APAP treatment. Expression levels were
normalized to β-actin. Data are presented as the mean ± S.D. (n = 5 animals). Asterisks (*) show
statistical differences (P < 0.05) between groups.
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Figure 3.6.4. Cyp2e1, Nqo1, Ho-1 and Gclc mRNA expression in male and female WT and
Nrf2 -/- mice following APAP in A) Choroid plexus and B) brain (sans CP). Nqo1 and Ho-1
mRNA is higher in WTF compare to WTM in both blood brain interfaces (CP and BBB). No
gender-related differences in basal expression of Gclc and Cyp2e1 were observed in both genders
of WT animals. Nqo1 and Ho-1 mRNA expression increased in CP following APAP in WTM.
There is also an increased in WTM Cyp2e1, Nqo1 and Gclc expression in BBB after APAP. There
is decreased expression of Nqo1, Ho-1 and Gclc mRNA after APAP in Nrf2-/- males. However,
no changes in these genes were observed in male CP. Interestingly, there is elevation of Cyp2e1
and Nqo1 expression in CP following APAP in Nrf2-/- females. Data are presented as the mean ±
S.D. (n = 5 animals). Asterisks (*) show statistical differences (P < 0.05) between groups.
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Figure 3.6.5. Summary of sex differences in CP and brain after APAP hepatotoxic dose
cytoprotective elements. Our lab has found that female expressed higher oveall expression of
cytoprotective genes at brain interfaces (Flores et al., 2017). These efflux transporters play an
important detoxifying role, and they have been shown to be up-regulated in hepatocytes after toxic
acetaminophen treatment. The mechanistic involvement of Mrps in the acetaminophen pathway
is unknown.
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Table 1: Primer sequences for quantitative real-time-PCR

Gene name
ATP-binding cassette, sub-

Gene symbol
Abcc2

Abcc4

Nrf2

Nqo1

F: 5’-TTT AGG GTC GTC TTG GCA AC-3’
R: 5’-GTC TTC TCT GAA TGG GCC AG-3’

dehydrogenase 1
Heme oxygenase 1

F: 5’-TCT ATG TGC CTC CAA AGG-3’
R: 5’-CTC AGC ATG ATG GAC TTG GA-3’

related factor 2
NAD(P)H quinone

F: 5’-TAATGGAAGCAGACAAGGCCCAGA-3’
R: 5’-AGAGGCCAGTGCAGATACATGGTT-3’

family C (MRP), member 4
Nuclear factor erythroid 2-

F: 5’-TCC AGG ACC AAG AGA TTT GC-3’
R: 5’-TCT GTG AGT GCA AGA GAC AGG T-3’

family C (/MRP), member 2
ATP-binding cassette, sub-

Primer forward and reverse sequences

Ho-1

F: 5’-GAGCCTGAATCGAGCAGAAC-3’
R: 5’-CCTTCAAGGCCTCAGACAAA-3’

Glutamate--cysteine ligase

Gclc

R: 5’-TTCATGATCGAAGGACACCA-3’

catalytic subunit
Cytochrome P450 (CYP)

F: 5’-CTGCACATCTACCACGCAGT-3’

Cyp2e1

F: 5’-GGGACATTCCTGTGTTCCAG-3’
R: 5’-CTTAGGGAAAACCTCCGCAC-3’

Actin, beta

Actb

R: 5’-GCA GAC AGC CAA GGA GCC CAA AGA CC-3’
F: 5’-GCA ACG AGC GGT TCC G-3’
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Table 2. Summary of sex differences in CP and brain after APAP-induced mRNA change
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CHAPTER 4

CHAPTER 4. Summary, Major Conclusions and Prospects

Sometimes called the “kidney” of the brain, the choroid plexus (CP) aids in the clearance of
various soluble compounds such as organic anions (OA) from the CSF to the blood. Both the
blood-cerebrospinal fluid barrier (BCSFB or CP) and the blood-brain barrier (BBB), protect the
brain from endogenous and exogenous compounds, including a variety of therapeutics, by
exporting them from the cerebrospinal fluid (CSF) or brain parenchyma interstitial space (IS) to
the blood for ultimate excretion. Although the CP remains an understudied tissue, because it is
responsible for the secretion and maintenance of the cerebrospinal fluid (CSF), it is important to
study the transporters that help with its active barrier functions. The main portion of this research
examined the gender differences in expression of Mrps and cytoprotective genes in the mouse
brain interfaces. Efflux transporters Mrp1 and Mrp4 are co-localized to the basolateral membrane
of the CP, whereas Mrp2 (Abcc2) is located in the apical membrane, together they may function
in the prevention of substrate/drug or drug metabolite intracellular accumulation. Previous studies
have reported sexual dimorphism of Abc-type transporters in the kidney and liver of adult mice,
however, the gender-specific characterization of the Mrp efflux transporters in the brain is still
limited. Our aim was to examine basal gender differences in expression of Mrp transporters, Nrf2
and Nrf2-dependent genes (Nqo1 and Ho-1) in the brain-barriers. With qPCR and westernblot
analysis we demonstrate there are gender-specific expression patterns of several key cytoprotective
genes and proteins in the CP and brain. Previous studies have shown higher expression of Mrp1,
Mrp2 and Mrp4 in female mouse liver and kidney. We found that in the CP, among the Mrps we
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studied only Mrp4 mRNA and protein expression was found to be higher in females compared to
males. The same renal/hepatic gender-specific pattern was found to be true for mRNA and protein
expression of Mrp1, Mrp2 and Mrp4 in brain tissue without CP. In addition, mRNA and protein
of Nrf2-dependent genes, Ho-1 and Nqo1, were found to be higher in females in both brain
barriers. Though the hepatic basal expression of Nrf2 is reportedly higher in males than females
(Rohrer et al., 2014), we found no gender-dependent differences in CP.

We further investigated the function of Mrp4 in the CP by performing transport assays. This
gender-specific expression of Mrp4 we found in the CP could lead to altered drug absorption and
excretion between male and females. Although Mrps have a diverse substrate specificity and their
functions may vary, the Mrps play a key role in cellular protection by removing xenobiotics and
endogenous substrates that can accumulate in tissue and lead to toxicity. Similarly, Mrp4 can
transport endogenous compounds like cAMP. Interestingly, when we isolate fresh male and female
CP and incubate them in an artificial CSF bath with a fluorescently labeled cAMP (cAMP analog),
we observed that there were gender differences in the accumulation of this probe. The active
accumulation of the model substrate fluo-cAMP clearly suggest that the gender difference in
mRNA and protein expression of Mrp4 can be translated to functional differences in substrate
handling capacity. Consistent with previous studies, fluo-cAMP proved to be a good substrate
model to study Mrp4 function. Compared with other Mrps, Mrp4 has a higher affinity for cAMP
(Chen et al., 2002).

In-vivo, cAMP may be involved in intercellular signaling and the

physiological contribution of Mrp4 to the regulation of cyclic nucleotide signaling will need to be
further examined.
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Previuos studies have reported that in liver Mrp2 and Mrp4 expression can be altered in
response to cellular stress differentially in male and female (Rohrer et al., 2014). Although the
mechanism is not completely clear some ATP-binding cassette transporters (Abc transporters) and
antioxidant genes are positively induced by the activation of Nrf2 and contribute to the protection
against potential harmful components. There is limited data on sex differences in the cellular
stress-response of these transporters in brain. Given the gender differences reported here in the
CP and BBB, we explored the expression of these cytoprotective elements in response to a
hepatotoxic dose of acetaminophen (APAP). Consistent with the literature, ALT activity was
significantly elevated in both WT and Nrf2-/- male mice following APAP treatment, but no
increases in ALT were observed in either genotype of female mice. Efflux transporters, Nrf2 and
Nrf2 related genes responded to APAP treatment in a gender specific manner at the brain
interfaces. Mrp2 and Mrp4 mRNA expression was induced after 24hrs APAP administration in
WT male brain and were reduced in Nrf2-/- male brain. No changes in Mrp2 and Mrp4 mRNA
expression in CP after APAP treatment. In females, no alterations in expression in either genotype
in these brain interfaces following APAP were observed. Our results, however, showed that female
brain and CP have overall higher basal expression of cytoprotective genes compared to males.
Furthermore, Nrf2 was found to be tissue specific. In the CP, Nrf2 mRNA did not show gender
differences. In contrast, basal Nrf2 mRNA at BBB was found to be higher in the females. Possibly
other transcription factors may contribute to the higher basal expression of these cytoprotective
genes in the CP. In these studies, doses of APAP that are considered to be hepatotoxic lead to
alterations in drug transporter expression in males, but did not cause such alterations in female
brain interfaces. Further studies are needed to understand the basis for sex-differences in the
cellular response of the BBB and BCSFB to drugs.
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Recent studies in our laboratory investigated the role of the transcription factor nuclear factor
erythroid 2-related factor 2 (Nrf2), the efflux transporter multidrug resistance-associated protein 4
(Mrp4), and the drug metabolizing enzyme flavin-containing mono-oxygenase 3 (Fmo3) in sexdependent susceptibility to APAP-induced hepatotoxicity in mice. However, the expression and
potential role of Nrf2, Fmo3, and Mrp4 in the responsiveness of male and female mouse kidneys
to toxic doses of APAP has not been investigated. Here we reported gender-dependent expression
of cytoprotective elements in the kidney in response to a hepatotoxic dose of acetaminophen.
Immunoblots and qRT-PCR analysis revealed that basal renal Fmo3 gene and protein expression
is significantly greater in male than female mice, while Mrp4 expression is higher in WT females.
Nrf2 expression was higher in males than in females. This corresponds with hepatic basal
expression, suggesting that male and female Nrf2 expression levels are similar between liver and
kidney. We evaluated the urea nitrogen (BUN) values in the plasma following APAP and they
were within the normal values for both genders and the kidney histology was normal. In response
to APAP treatment, no changes in renal expression of Mrp4 or Fmo3 were observed in either
gender, consistent with the absence of renal pathology. While APAP produced hepatocellular
damage in males at 400mg/kg APAP, this dose did not result in any renal damage. However we
cannot rule out that 24hr might not be enough time to detect renal damage, and that maybe by
extending the time we could observe some renal damage.

In summary, we show here that basal expressions of the Mrps and several antioxidantrelevant genes are higher in females compared to males. Although our experiments show gender
differences in the expression of several of these genes, the mechanism remains unknown. For the
first time we showed that Mrp4 higher basal mRNA and protein expression in female compare to
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male translate to a functional role. The present results highlight significant gender differences in
the transport of the Mrp4 substrate fluo-cAMP. The physiological contribution of Mrp4 to
regulation of cyclic nucleotide signaling will need to be further examined. Our results suggest that
the movement of endogenous/ exogenous molecules between plasma and brain compartments may
be gender dependent. In chapter 3, female mouse brain and CP responded differently to an
hepatotoxic dose of APAP than male. Furthermore, our studies with the Nrf2-/- mice strongly
indicate that this transcription factor is not responsible for the resistance of female mice to APAPinduced hepatotoxicity, suggesting that other mechanisms must contribute to this gender
difference. Further characterization of gender-specific expression of antioxidant defense genes in
the CP and brain following toxicant exposure will help us understand potential gender differences
in brain drug response. Whether other regulatory factors may contribute to the higher basal
expression of cytoprotective genes in CP and brain of female mice remains to be determined.
Moreover, the work describe herein underscore the importance of the gender-dependent drug
response specificity of these cytoprotective genes in the brain interfaces and their overall impact
in CP functions.
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APENDIX 1
Table A.1. Renal and hepatic gender-related differences in the Mrp expression
in mouse
Transporters
and
cytoprotective
genes
Mrp1

Subcellular
localization

Gender related
differences (Basal)

Reference

Basolateral
(L,K,CP)
Apical (K,CP)
Canaliculi (L)
Basolateral
(L,K)
Apical (K),
Basolateral
(L,CP)
Basolateral
(K,CP?)

female>male (L,K)*#

Rao et al., 1999,
Maher, J et al., 2005
Maher, J et al., 2005

ND

Nrf2
Nqo1

Basolateral
(L,K)
Apical (K,CP)
Canaliculi (L)
Nuclear
Cytosolic

Ho-1

Cytosolic

female>male (L)*

Mrp2
Mrp3
Mrp4

Mrp5

Mrp6
Bcrp

ND
male>female (L,
K)*#
female>male (L,K)*#

Maher, J et al., 2005
Roberts et al., 2008,
Assem et al., 2004

ND

Males>females

Beger et al., 2015

male>female (L)*#
female>male (L)*

Rohrer et al., 2014
Rohrer et al., 2014

Rohrer et al., 2014
Gclc

Cytosolic

female>male (L)*

Rohrer et al.,F 2014

Choroid Plexus (CP), Kidney (K), Liver (L)
Not determine
(*) protein & (#) gene expression
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APENDIX 2
Table A.2. List of genes and biological functions

Cellular process

Gene

Biological Function

Glutathione Homeostasis

Glutamate-cysteine ligase
catalytic subunit

Drug Metabolism

NAD(P)H quinone
oxidoreductase 1 (Nqo1)

Stress response

Heme oxygenase (Ho-1)

Encodes for the rate-limiting enzyme in
glutathione synthesis, an aspect of drug
metabolism.
Catalyze formation of γ glutamylcysteine
This enzyme assists in removing
quinones that may result from
detoxification within the hepatocytes.
Reduce quinones and endogenous
antioxidants, scavenge superoxide
Encodes for an enzyme that catalyzes the
breakdown of heme to carbon monoxide,
biliverdin, and free iron. Heme levels
will elevate in the event of oxidative
stress.
Stress sensor. Regulates the expression
of antioxidant proteins that protect
against oxidative damage triggered by
injury and inflammation.
Efflux chemicals across cell membrane

Nuclear factor erythroid 2–
related factor 2 (Nrf2)

Excretion/Transporters

Multidrug Resistance Protein
1 (Mrp1)
Multidrug Resistance Protein
4 (Mrp4)

Efflux chemicals across cell membrane
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APENDIX 3
Table A.3. Mrp substrate specificity

Transporter
Mrp1

Endogenous
substrates
Glutathione, E217βG,
bilirubin glucuronides,
leukotriene C4

Mrp2

Divalent bile salts,
glutathione,
glutathione
conjugates, bilirubin,
E217βG,
leukotriene C4

Mrp4

Bile salts, E217βG,
leukotrienes, cyclic
nucleotides,
prostanoides, folates

Mrp5

Cyclic nucleotides

Other
Metotrexate (MTX),
doxorubicin,
vincristine,
chlorambucil,
cyclophosphamide,
etc.
MTX, vinblastine,
etoposide,
vincristine, cisplatin,
doxorubicin,
cyclophosphamide,
arsenic-glutathione
complexes, etc.
MTX, topotecan,
adefovir, tenofovir,
PAH, eicosanoids,
urate, and conjugated
steroids, etc.
MTX, antimetabo_
lites, etc.
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APENDIX 4
Figure A1. Tissue distribution of Abc-type transporters. Abc transporters are expressed in
gender-specific patterns in liver and kidney. Interesting, Mrp4 is consistently higher in female at
both mRNA and protein levels in liver, kidneys, brain and CP. However, the expression of this
transporter varies across tissue and might be indicative of specific organ-function. For example,
Mrp4 is highly express in kidneys and CP, while in liver the expression of this transporter is lower.
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